IL42418A - An osmotic device for dispensing an active agent at a controlled rate - Google Patents

An osmotic device for dispensing an active agent at a controlled rate

Info

Publication number
IL42418A
IL42418A IL42418A IL4241873A IL42418A IL 42418 A IL42418 A IL 42418A IL 42418 A IL42418 A IL 42418A IL 4241873 A IL4241873 A IL 4241873A IL 42418 A IL42418 A IL 42418A
Authority
IL
Israel
Prior art keywords
dispensing
active agent
controlled rate
osmotic device
osmotic
Prior art date
Application number
IL42418A
Other languages
English (en)
Other versions
IL42418A0 (en
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of IL42418A0 publication Critical patent/IL42418A0/xx
Publication of IL42418A publication Critical patent/IL42418A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A61F6/142—Wirelike structures, e.g. loops, rings, spirals
    • A61F6/144—Wirelike structures, e.g. loops, rings, spirals with T-configuration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
IL42418A 1972-06-05 1973-05-31 An osmotic device for dispensing an active agent at a controlled rate IL42418A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US00259469A US3845770A (en) 1972-06-05 1972-06-05 Osmatic dispensing device for releasing beneficial agent

Publications (2)

Publication Number Publication Date
IL42418A0 IL42418A0 (en) 1973-07-30
IL42418A true IL42418A (en) 1975-07-28

Family

ID=22985088

Family Applications (1)

Application Number Title Priority Date Filing Date
IL42418A IL42418A (en) 1972-06-05 1973-05-31 An osmotic device for dispensing an active agent at a controlled rate

Country Status (12)

Country Link
US (1) US3845770A (nl)
JP (1) JPS596843B2 (nl)
AR (1) AR199301A1 (nl)
BR (1) BR7304196D0 (nl)
CH (1) CH578464A5 (nl)
ES (1) ES415568A1 (nl)
FR (1) FR2188568A5 (nl)
GB (1) GB1415210A (nl)
IE (1) IE39952B1 (nl)
IL (1) IL42418A (nl)
NL (1) NL163721C (nl)
ZA (1) ZA733734B (nl)

Families Citing this family (2063)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3948254A (en) * 1971-11-08 1976-04-06 Alza Corporation Novel drug delivery device
US3996933A (en) * 1972-10-02 1976-12-14 Morton Gutnick Intrauterine contraceptive devices and processes
US4325388A (en) * 1973-02-05 1982-04-20 Louis Bucalo Apparatus for collecting and processing body fluids
US3971376A (en) * 1973-02-26 1976-07-27 Ceskoslovenska Akademie Ved Method and apparatus for introducing fluids into the body
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
GB1465684A (en) * 1973-07-27 1977-02-23 Emmett L Contraceptive device
US4111196A (en) * 1973-07-27 1978-09-05 Lionel C. R. Emmett Intrauterine contraceptive device of c or omega form with tubular inserter and method of placement
US4018220A (en) * 1974-07-19 1977-04-19 Lionel C. R. Emmett Method of insertion for intrauterine device of C or omega form with tubular inserter
US4172446A (en) * 1974-12-20 1979-10-30 Louis Bucalo Apparatus for collecting body fluids
US4135514A (en) * 1974-12-23 1979-01-23 Alza Corporation Osmotic releasing system for administering ophthalmic drug to eye of animal
US3946734A (en) * 1975-02-19 1976-03-30 The United States Of America As Represented By The Secretary Of State Apparatus for controlling the release of a drug
ZA761193B (en) * 1975-03-19 1977-02-23 Procter & Gamble Controlled release articles
US3977404A (en) * 1975-09-08 1976-08-31 Alza Corporation Osmotic device having microporous reservoir
US4034758A (en) * 1975-09-08 1977-07-12 Alza Corporation Osmotic therapeutic system for administering medicament
US4036228A (en) * 1975-09-11 1977-07-19 Alza Corporation Osmotic dispenser with gas generating means
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031202A (en) * 1975-12-08 1977-06-21 The Procter & Gamble Company Controlled release contraceptive article
US4073833A (en) * 1975-12-08 1978-02-14 The Procter & Gamble Company Encapsulation process
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4058122A (en) * 1976-02-02 1977-11-15 Alza Corporation Osmotic system with laminated wall formed of different materials
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4207890A (en) * 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4218433A (en) * 1977-03-03 1980-08-19 Nippon Kayaku Kabushiki Kaisha Constant-rate eluting tablet and method of producing same
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4265874A (en) * 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
SE448203B (sv) * 1980-09-10 1987-02-02 Johan Alfred Olof Johansson formkropp framstelld av agar och/eller agaros och/eller ett derivat derav innehallande farmakologiskt verksamt emne
US4439195A (en) * 1980-10-14 1984-03-27 Alza Corporation Theophylline therapy
US4455145A (en) * 1981-07-10 1984-06-19 Alza Corporation Dispensing device with internal drive
US4994031A (en) * 1981-07-13 1991-02-19 Alza Corporation Intravenous system for delivering a beneficial agent
US4790820A (en) * 1981-07-13 1988-12-13 Alza Corporation Parenteral agent dispensing equipment with drug releasing member
US4511353A (en) * 1981-07-13 1985-04-16 Alza Corporation Intravenous system for delivering a beneficial agent
US4740201A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4857052A (en) * 1981-07-13 1989-08-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4985017A (en) * 1981-07-13 1991-01-15 Alza Corporation Parenteral therapeutical system comprising drug cell
US4973307A (en) * 1981-07-13 1990-11-27 Alza Corporation Method for administering drugs to a patient
US4552555A (en) * 1981-07-31 1985-11-12 Alza Corporation System for intravenous delivery of a beneficial agent
USRE34365E (en) * 1981-07-13 1993-08-31 Intravenous system for delivering a beneficial agent
US5069671A (en) * 1981-07-13 1991-12-03 Alza Corporation Intravenous medication
US4740198A (en) * 1981-10-09 1988-04-26 Alza Corporation Method of administering intravenous drug using rate-controlled dosage form
US4432756A (en) * 1981-11-27 1984-02-21 Alza Corporation Parenteral controlled therapy
US4871360A (en) * 1981-07-31 1989-10-03 Alza Corporation System for intravenous delivery of a beneficial drug at a regulated rates
US4525162A (en) * 1981-07-31 1985-06-25 Alza Corporation Parenteral controlled delivery
GB2107191B (en) * 1981-07-31 1984-08-30 Alza Corp Parenteral delivery system
US4439194A (en) * 1981-09-08 1984-03-27 Merck & Co., Inc. Water and drug delivery system for suppository use
US4741734A (en) * 1981-10-09 1988-05-03 Alza Corporation Releasing means for adding agent using releasing means to IV fluid
US4740103A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740199A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740197A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent via polymer delivery
US4741735A (en) * 1981-10-09 1988-05-03 Alza Corporation Intravenous system for delivering a beneficial agent
US4740200A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4586922A (en) * 1981-10-09 1986-05-06 Alza Corporation Intravenous system for delivering a beneficial agent
US4416659A (en) * 1981-11-09 1983-11-22 Eli Lilly And Company Sustained release capsule for ruminants
US4548599A (en) * 1981-11-27 1985-10-22 Alza Corporation Parenteral controlled therapy
US4479793A (en) * 1981-11-27 1984-10-30 Alza Corporation Parenteral administration using drug delivery device
US4484909A (en) * 1981-11-27 1984-11-27 Alza Corporation Parenteral therapy using solid drug
US4579553A (en) * 1981-11-27 1986-04-01 Alza Corporation Parenteral controlled therapy
US4552556A (en) * 1981-11-27 1985-11-12 Alza Corporation Parenteral controlled therapy
US4583981A (en) * 1981-11-27 1986-04-22 Alza Corporation Parenteral controlled therapy, using a porous matrix with parenteral agent
US4479794A (en) * 1981-11-27 1984-10-30 Alza Corporation System for intravenous therapy
US4493702A (en) * 1981-11-27 1985-01-15 Alza Corporation Parenteral administration using osmotically motivated delivery system
US4484921A (en) * 1982-02-01 1984-11-27 Alza Corporation Theophylline therapy utilizing osmotic delivery
US4475916A (en) * 1982-03-18 1984-10-09 Merck & Co., Inc. Osmotic drug delivery system
US4439196A (en) * 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4455143A (en) * 1982-03-22 1984-06-19 Alza Corporation Osmotic device for dispensing two different medications
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4515585A (en) * 1982-05-24 1985-05-07 Alza Corporation System for parenteral administration of agent
US4908019A (en) * 1982-05-24 1990-03-13 Alza Corporation Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
US4664650A (en) * 1982-05-24 1987-05-12 Alza Corporation Apparatus for parenteral infusion of fluid containing beneficial agent
US4489056A (en) * 1982-06-30 1984-12-18 Merck & Co., Inc. Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4553973A (en) * 1982-07-12 1985-11-19 Alza Corporation Process for preparing osmotic device
US4539004A (en) * 1982-09-22 1985-09-03 Alza Corporation Self-driven pump assembly and method of operation
US4522625A (en) * 1982-09-29 1985-06-11 Alza Corporation Drug dispenser comprising wall formed of semipermeable member and enteric member
US4552561A (en) * 1982-12-23 1985-11-12 Alza Corporation Body mounted pump housing and pump assembly employing the same
US4859667A (en) * 1983-01-21 1989-08-22 Merck Frosst Canada, Inc. Pharmaceutical compositions of phenothiazone derivatives and analogs
US4667032A (en) * 1983-01-21 1987-05-19 Merck Frosst Canada, Inc. Phenothiazone derivatives and analogs
US4576604A (en) * 1983-03-04 1986-03-18 Alza Corporation Osmotic system with instant drug availability
US4690682A (en) * 1983-04-15 1987-09-01 Damon Biotech, Inc. Sustained release
US4789516A (en) * 1983-04-15 1988-12-06 Damon Biotech, Inc Production of sustained released system
US4503030A (en) * 1983-06-06 1985-03-05 Alza Corporation Device for delivering drug to certain pH environments
US4610686A (en) * 1983-11-02 1986-09-09 Alza Corporation Controlled delivery of haloperidol by an osmotic delivery system
GB2150830B (en) * 1983-12-05 1987-08-19 Alza Corp Drug dispenser
US4612186A (en) * 1984-03-19 1986-09-16 Alza Corporation Method for establishing blood levels of biocide in animals
US4692336A (en) * 1984-03-19 1987-09-08 Alza Corporation Self controlled release device for administering beneficial agent to recipient
US4927633A (en) * 1984-03-19 1990-05-22 Alza Corporation Dispenser for delivering drug to livestock
US4844984A (en) * 1984-03-19 1989-07-04 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
US5000957A (en) * 1984-03-19 1991-03-19 Alza Corporation Dispenser comprising hydrophilic osmopolymer
US4624945A (en) * 1984-03-19 1986-11-25 Alza Corporation Dispensing system with means for increasing delivery of beneficial agent from the system
US4729793A (en) * 1985-08-09 1988-03-08 Alza Corporation Composition for manufacturing wall of dispensing device
US4684524A (en) * 1984-03-19 1987-08-04 Alza Corporation Rate controlled dispenser for administering beneficial agent
US4717566A (en) * 1984-03-19 1988-01-05 Alza Corporation Dosage system and method of using same
US4814180A (en) * 1984-03-21 1989-03-21 Alza Corporation Agent dispenser comprising a semipermeable wall surrounding single-piece or two-piece container
US4716031A (en) * 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
GB2155889B (en) * 1984-03-21 1988-03-02 Alza Corp Dispenser-capsule
US4692326A (en) * 1984-03-21 1987-09-08 Alza Corporation Dispenser comprising inner positioned soft or hard capsule
US4678467A (en) * 1984-03-21 1987-07-07 Alza Corporation Dispenser comprising capsule with volume displacing member
US4663148A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4663149A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising inner and outer walls functioning as cooperative unit
US4615698A (en) * 1984-03-23 1986-10-07 Alza Corporation Total agent osmotic delivery system
US4511351A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4596555A (en) * 1984-05-14 1986-06-24 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4511352A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system with in-line container
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4769027A (en) * 1984-08-15 1988-09-06 Burroughs Wellcome Co. Delivery system
EP0246715A3 (en) * 1984-12-03 1988-02-03 BAXTER INTERNATIONAL INC. (a Delaware corporation) Apparatus for the safe delivery of a beneficial agent to a patient
US4680172A (en) * 1985-03-05 1987-07-14 Ciba-Geigy Corporation Devices and methods for treating memory impairment
US4765985A (en) * 1985-03-05 1988-08-23 Ciba-Geigy Corporation Devices and methods for treating memory impairment
JPS61153350U (nl) * 1985-03-13 1986-09-22
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
US4717568A (en) * 1985-08-09 1988-01-05 Alza Corporation Laminar arrangement for increasing delivery of beneficial agent from dispenser
US4717718A (en) * 1985-08-09 1988-01-05 Alza Corporation Device for the controlled delivery of a beneficial agent
US4675174A (en) * 1985-08-16 1987-06-23 Alza Corporation Veterinary dispenser delivering beneficial agent by gas power generated in situ
US4865598A (en) * 1985-08-16 1989-09-12 Alza Corporation Dispensing system for administering beneficial agent
US4966767A (en) * 1985-08-16 1990-10-30 Alza Corporation Ruminant dispensing device comprising agent displacement member
US4643731A (en) * 1985-08-16 1987-02-17 Alza Corporation Means for providing instant agent from agent dispensing system
US5098425A (en) * 1985-08-16 1992-03-24 Alza Corporation Method of administering a ruminant dispensing device comprising density member dispersed in hydrogel member
US4871544A (en) * 1985-08-16 1989-10-03 Alza Corporation Ruminant dispensing device
US4704118A (en) * 1985-08-16 1987-11-03 Alza Corporation Ruminant dispensing device with thermo-activated memory
US4955881A (en) * 1985-08-16 1990-09-11 Alza Corporation Ruminant dispensing device
US4883667A (en) * 1985-08-16 1989-11-28 Alza Corporation Process for forming dispensing device
US4963141A (en) * 1985-08-16 1990-10-16 Alza Corporation Dispensing system for administering beneficial agent formulation to ruminants
US4756314A (en) * 1985-10-28 1988-07-12 Alza Corporation Sweat collection patch
US4680266A (en) * 1985-11-21 1987-07-14 Contraves Ag Cell culture chamber with means for automatic replenishment of nutrient
US5008112A (en) * 1985-12-16 1991-04-16 International Minerals & Chem. Corporation Device for the extended delivery of diffusible agents
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US4867969A (en) * 1986-02-07 1989-09-19 Alza Corporation Hydrogel formulation for administering non-steroidal drugs
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
DE3786030T2 (de) 1986-03-27 1993-12-02 Merck Frosst Canada Inc Tetrahydrocarbazole Ester.
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
US4847093A (en) * 1986-06-19 1989-07-11 Alza Corporation Dosage form with means for governing rate of gas formation
US4838862A (en) 1986-08-04 1989-06-13 Pharmetrix Corp. Portable controlled release osmotic infusion device
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
ES2039287T3 (es) * 1987-01-14 1993-09-16 Ciba-Geigy Ag Procedimiento para la obtencion de un sistema terapeutico peroral para productos activos dificilmente solubles.
US4801461A (en) 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
US4915952A (en) * 1987-02-27 1990-04-10 Alza Corporation Composition comprising drug, HPC, HPMC and PEO
US5023076A (en) * 1987-02-27 1991-06-11 Alza Corporation Lamina comprising carboxyvinyl polymer
US4888416A (en) * 1987-03-30 1989-12-19 International Minerals & Chemical Corp. Method for stabilizing somatotropins
US5499979A (en) * 1987-06-25 1996-03-19 Alza Corporation Delivery system comprising kinetic forces
US5110597A (en) * 1987-06-25 1992-05-05 Alza Corporation Multi-unit delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US5938654A (en) * 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US4957494A (en) * 1987-06-25 1990-09-18 Alza Corporation Multi-layer delivery system
US5023088A (en) * 1987-06-25 1991-06-11 Alza Corporation Multi-unit delivery system
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US4880631A (en) * 1987-09-24 1989-11-14 Merck & Co., Inc. Controlled porosity osmotic pump
US4886668A (en) * 1987-09-24 1989-12-12 Merck & Co., Inc. Multiparticulate controlled porosity osmotic pump
US4950486A (en) * 1987-10-02 1990-08-21 Alza Corporation Dosage form for treating cardiovascular diseases
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US5030203A (en) * 1987-11-16 1991-07-09 Baxter International Inc. Ampule for controlled administration of beneficial agent
JP2590358B2 (ja) * 1988-03-01 1997-03-12 正雄 五十嵐 子宮内膜症治療用の子宮内又は膣内投与製剤
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US4892739A (en) * 1988-04-25 1990-01-09 Ciba-Geigy Corporation Osmotic continuous dispensing oral delivery system containing a pharmaceutically acceptable active agent having a improved core membrane adhesion properties
US5006346A (en) * 1988-04-28 1991-04-09 Alza Corporation Delivery system
US5024842A (en) * 1988-04-28 1991-06-18 Alza Corporation Annealed coats
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US5160743A (en) * 1988-04-28 1992-11-03 Alza Corporation Annealed composition for pharmaceutically acceptable drug
US4859470A (en) * 1988-06-02 1989-08-22 Alza Corporation Dosage form for delivering diltiazem
US4966769A (en) * 1988-06-02 1990-10-30 Alza Corporation Method for delivering dosage form for diltiazem
US5028434A (en) * 1988-07-21 1991-07-02 Alza Corporation Method for administering nilvadipine for treating cardiovascular symptoms
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5096716A (en) * 1988-09-01 1992-03-17 Alza Corporation Dosage form for administering calcium antagonist nicardipine
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5030456A (en) * 1988-11-07 1991-07-09 Alza Corporation Dosage form for treating cardiovascular diseases
US4997658A (en) * 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US5376383A (en) * 1988-11-21 1994-12-27 Merck & Co., Inc. Method for enhancing the lowering of plasma-cholesterol levels
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5728088A (en) * 1988-12-13 1998-03-17 Alza Corporation Osmotic system for delivery of fluid-sensitive somatotropins to bovine animals
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5174999A (en) * 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Hydrogel-operated release devices
US5030452A (en) * 1989-01-12 1991-07-09 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5108756A (en) * 1989-01-12 1992-04-28 Pfizer Inc. Dispensing devices powered by lyotropic liquid crystals
US5186942A (en) * 1989-01-30 1993-02-16 Alza Corporation Nicardipine therapy
DD295760A5 (de) * 1989-01-31 1991-11-14 Martin-Luther-Universitaet Halle Wittenberg,De Arzneistoffreigabesystem mit kotrollierter wirkstoffreisetzung
US4969872A (en) * 1989-03-08 1990-11-13 Alza Corporation Intravenous system for delivering a beneficial agent with delivery rate control via permeable surface area variance
US5019396A (en) * 1989-05-12 1991-05-28 Alza Corporation Delivery dispenser for treating cardiac arrhythmias
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5021053A (en) * 1989-07-14 1991-06-04 Alza Corporation Oral osmotic device with hydrogel driving member
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US6361795B1 (en) 1989-09-05 2002-03-26 Alza Corporation Method for lowering blood glucose
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US20020197309A1 (en) * 1989-09-05 2002-12-26 Kuczynski Anthony L. Method for lowering blood glucose
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US5591454A (en) * 1989-09-05 1997-01-07 Alza Corporation Method for lowering blood glucose
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5200197A (en) * 1989-11-16 1993-04-06 Alza Corporation Contraceptive pill
US5098714A (en) * 1989-11-16 1992-03-24 Alza Corporation Osmotic, oral dosage form for fertility control
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5071607A (en) * 1990-01-31 1991-12-10 Alza Corporatino Method and apparatus for forming a hole in a drug dispensing device
US5024663A (en) * 1990-02-21 1991-06-18 Alza Corporation Self-contained suction pump
US5178866A (en) * 1990-03-23 1993-01-12 Alza Corporation Dosage form for delivering drug to the intestine
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5017381A (en) * 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5192550A (en) * 1990-05-07 1993-03-09 Alza Corporation Dosage form for treating central nervous system disorders
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5128145A (en) * 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
US5234694A (en) * 1990-07-11 1993-08-10 Alza Corporation Method for increasing feed efficiency in animals
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5238687A (en) * 1990-07-11 1993-08-24 Alza Corporation Delivery device with a protective sleeve
US5147654A (en) * 1990-07-23 1992-09-15 Alza Corporation Oral osmotic device for delivering nicotine
WO1992002212A2 (en) * 1990-08-07 1992-02-20 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
US5589511A (en) * 1990-08-13 1996-12-31 Sepracor Inc. Method for treating migraine headaches using optically pure S(+) fluoxetine
US5104899A (en) * 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
US5232705A (en) * 1990-08-31 1993-08-03 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy
US5246709A (en) * 1990-09-10 1993-09-21 Alza Corporation Antiemetic therapy
US5431921A (en) * 1990-09-28 1995-07-11 Pfizer Inc Dispensing device containing a hydrophobic medium
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
US5861166A (en) * 1991-03-12 1999-01-19 Alza Corporation Delivery device providing beneficial agent stability
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US5198229A (en) * 1991-06-05 1993-03-30 Alza Corporation Self-retaining gastrointestinal delivery device
US5227167A (en) * 1991-06-11 1993-07-13 Alza Corporation Long-term delivery device including hydrophobic loading dose
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5801141A (en) * 1991-06-24 1998-09-01 American Cyanamid Company Implant compositions containing a biologically active protein, peptide or polypeptide
US5160744A (en) * 1991-06-27 1992-11-03 Alza Corporation Verapmil therapy
US5252338A (en) * 1991-06-27 1993-10-12 Alza Corporation Therapy delayed
US5190765A (en) * 1991-06-27 1993-03-02 Alza Corporation Therapy delayed
US6764697B1 (en) 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
US5178867A (en) * 1991-08-19 1993-01-12 Alza Corporation Dosage form for delivering drug in short-time period
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5266332A (en) * 1991-12-06 1993-11-30 Alza Corporation Method for administering anti-Parkinson drug
US5200195A (en) * 1991-12-06 1993-04-06 Alza Corporation Process for improving dosage form delivery kinetics
US5254349A (en) * 1991-12-06 1993-10-19 Alza Corporation Process for lessening irritation caused by drug
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
US5688518A (en) * 1992-02-27 1997-11-18 Alza Corporation Antidepressive therapy
US5246711A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating dysthymia
US5185158A (en) * 1992-02-27 1993-02-09 Alza Corporation Dosage form comprising succinimide drug for treating depressive disorders and composition comprising same
US5330762A (en) * 1992-02-27 1994-07-19 Alza Corporation Tandospiaine antidepressive therapy
US5246710A (en) * 1992-02-27 1993-09-21 Alza Corporation Dosage form for treating cyclothymia
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5869097A (en) 1992-11-02 1999-02-09 Alza Corporation Method of therapy comprising an osmotic caplet
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
MX9401351A (es) * 1993-02-22 1994-08-31 Alza Corp Composiciones para suministro oral para agentes activos.
EP0621032B1 (en) * 1993-04-23 2000-08-09 Novartis AG Controlled release drug delivery device
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
DE4342173A1 (de) * 1993-12-10 1995-06-14 Lohmann Therapie Syst Lts Pharmazeutische Formulierung zur Prophylaxe bzw. Vorbehandlung einer Vergiftung durch phosphororganische Cholinesterasehemmer
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US5770076A (en) * 1994-03-07 1998-06-23 The Regents Of The University Of California Micromachined capsules having porous membranes and bulk supports
US5798042A (en) * 1994-03-07 1998-08-25 Regents Of The University Of California Microfabricated filter with specially constructed channel walls, and containment well and capsule constructed with such filters
US5985164A (en) * 1994-03-07 1999-11-16 Regents Of The University Of California Method for forming a filter
US5985328A (en) * 1994-03-07 1999-11-16 Regents Of The University Of California Micromachined porous membranes with bulk support
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US6077533A (en) * 1994-05-25 2000-06-20 Purdue Pharma L.P. Powder-layered oral dosage forms
US5411745A (en) * 1994-05-25 1995-05-02 Euro-Celtique, S.A. Powder-layered morphine sulfate formulations
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5460826A (en) * 1994-06-27 1995-10-24 Alza Corporation Morphine therapy
US5529787A (en) * 1994-07-07 1996-06-25 Alza Corporation Hydromorphone therapy
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
DE4431653C2 (de) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Manteltablette zur kontrollierten Freisetzung von Wirkstoffen, ein Verfahren zu ihrer Herstellung und ihre Verwendung
US6491945B1 (en) * 1994-09-16 2002-12-10 Alza Corporation Hydrocodone therapy
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5614578A (en) * 1994-10-28 1997-03-25 Alza Corporation Injection-molded dosage form
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5595759A (en) * 1994-11-10 1997-01-21 Alza Corporation Process for providing therapeutic composition
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
US5595997A (en) 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US5651979A (en) * 1995-03-30 1997-07-29 Gel Sciences, Inc. Apparatus and method for delivering a biologically active compound into a biological environment
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5817335A (en) * 1995-05-26 1998-10-06 Alza Corporation Osmotic device with high drug loading and delayed activation of drug delivery
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5800422A (en) * 1995-06-02 1998-09-01 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
US5713852A (en) * 1995-06-07 1998-02-03 Alza Corporation Oral dosage and method for treating painful conditions of the oral cavity
US5690952A (en) * 1995-06-07 1997-11-25 Judy A. Magruder et al. Implantable system for delivery of fluid-sensitive agents to animals
US5798119A (en) * 1995-06-13 1998-08-25 S. C. Johnson & Son, Inc. Osmotic-delivery devices having vapor-permeable coatings
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US5780058A (en) 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US6858589B2 (en) 1996-01-25 2005-02-22 Pharmacy And Therapeutic Advisory Consultancy Pty Ltd Methods of and compositions for potentiating the action of agents active on cell wall sites of the susceptible bacteria
AU2059297A (en) * 1996-03-12 1997-10-01 Alza Corporation Composition and dosage form comprising opioid antagonist
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US5902605A (en) * 1996-04-18 1999-05-11 Alza Corporation Drug delivery device with minimal residual drug retention
US7184826B2 (en) 1996-06-18 2007-02-27 Alza Corporation Device and method for enhancing transdermal flux of agents being delivered or sampled
WO1998006692A1 (en) * 1996-08-12 1998-02-19 Celgene Corporation Novel immunotherapeutic agents and their use in the reduction of cytokine levels
DK0936894T3 (da) * 1996-10-18 2001-11-19 Alza Corp Indretning til afgivelse af aktivt middel
AU729905B2 (en) 1996-10-18 2001-02-15 Alza Corporation Multiple flow path device for oral delivery of discrete units
US6024721A (en) 1996-10-18 2000-02-15 Alza Corporation Mixing system for an active agent delivery device
US6361796B1 (en) 1996-10-25 2002-03-26 Shire Laboratories, Inc. Soluble form osmotic dose delivery system
JP4863534B2 (ja) * 1996-10-25 2012-01-25 スパーナス ファーマシューティカルズ インコーポレイテッド 可溶形態浸透用量送達システム
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5948787A (en) * 1997-02-28 1999-09-07 Alza Corporation Compositions containing opiate analgesics
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
US6664397B1 (en) 1997-03-07 2003-12-16 Vernalis Research Limited Use of (+)mefloquine for the treatment of malaria
EP1304105B1 (en) * 1997-03-31 2006-07-19 Alza Corporation Diffusional implantable delivery system
CN1305462C (zh) * 1997-03-31 2007-03-21 阿尔萨公司 可扩散植入的释放系统
DE69807072T2 (de) * 1997-05-16 2003-04-03 Alza Corp., Mountain View Durchflussreglerkonfigurationen für ein wirkstoff abgebendes gerät
US5994148A (en) 1997-06-23 1999-11-30 The Regents Of University Of California Method of predicting and enhancing success of IVF/ET pregnancy
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
US6245042B1 (en) 1997-08-27 2001-06-12 Science Incorporated Fluid delivery device with temperature controlled energy source
US7060734B1 (en) 1997-09-09 2006-06-13 Alza Corporation Pharmaceutical coating composition and method of use
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
ATE282407T1 (de) * 1997-09-09 2004-12-15 Alza Corp Arzneimittel-überzugszubereitung und verfahren zu ihrer anwendung
UA66812C2 (uk) 1997-09-25 2004-06-15 Баєр Акцієнгезельшафт Препаративна форма лікарського засобу із регульованим вивільненням активної речовини
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
US6607751B1 (en) * 1997-10-10 2003-08-19 Intellipharamaceutics Corp. Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
AU1251499A (en) 1997-11-26 1999-06-15 Cerebrus Limited (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders
ATE216220T1 (de) 1997-12-05 2002-05-15 Alza Corp Osmotische darreichungsform mit zwei mantelschichten
US20040029962A1 (en) * 1997-12-12 2004-02-12 Chih-Ming Chen HMG-COA reductase inhibitor extended release formulation
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
US7323179B2 (en) * 1997-12-19 2008-01-29 Naomi Balaban Methods and compositions for the treatment and prevention of Staphylococcus and other bacterial infections
US20080219976A1 (en) * 1997-12-19 2008-09-11 Naomi Balaban Methods and compositions for treatment and prevention of staphylococcal infections
EP1041975B1 (en) 1997-12-22 2002-09-04 Alza Corporation Rate controlling membranes for controlled drug delivery devices
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2264226T3 (es) 1997-12-22 2006-12-16 Euro-Celtique S.A. Forma farmaceutica de dosificacion oral que comprende una combinacion de un agonista opioide y naltrexona.
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
CA2316887C (en) 1997-12-31 2008-04-08 Alza Corporation Osmotic drug delivery monitoring system and method
US7098206B2 (en) * 1998-01-21 2006-08-29 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6998400B2 (en) * 1998-01-22 2006-02-14 Smithkline Beecham Corporation Pharmaceutically active morpholinol
JP2002501891A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（＋）−ビュープロピオンの医薬用途
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
PE20000354A1 (es) 1998-04-03 2000-05-20 Advanced Medicine Inc Nuevos compuestos y usos anestesicos locales
US6462034B1 (en) 1998-04-03 2002-10-08 Theravance, Inc. Local anesthetic compounds and uses
US6196993B1 (en) 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6897305B2 (en) 1998-06-08 2005-05-24 Theravance, Inc. Calcium channel drugs and uses
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
NZ535055A (en) 1998-06-15 2006-04-28 Sepracor Inc Use of optically pure (-) norcisapride in the treatment of apnea, and other disorders
CN1312717A (zh) * 1998-06-15 2001-09-12 塞普拉科有限公司 光学纯度(+)—降西沙必利对治疗呼吸暂停、贪食症和其它疾病的用途
US6369039B1 (en) * 1998-06-30 2002-04-09 Scimed Life Sytems, Inc. High efficiency local drug delivery
US7890176B2 (en) * 1998-07-06 2011-02-15 Boston Scientific Neuromodulation Corporation Methods and systems for treating chronic pelvic pain
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
ES2238843T3 (es) 1998-07-24 2005-09-01 Seo Hong Yoo Disoluciones acuosas transparentes de acidos biliares.
US7303768B2 (en) 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) * 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6703050B1 (en) * 1998-09-04 2004-03-09 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
ATE311858T1 (de) * 1998-09-09 2005-12-15 Alza Corp Dosierungsform mit flüssiger formulierung
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US7906143B1 (en) 1998-10-05 2011-03-15 Intellipharmaceutics Corp Controlled release pharmaceutical delivery device and process for preparation thereof
US7101909B2 (en) * 1998-10-12 2006-09-05 Theravance, Inc. Calcium channel drugs and uses
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
GB9822854D0 (en) 1998-10-21 1998-12-16 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
KR20010075676A (ko) 1998-11-02 2001-08-09 스톤 스티븐 에프. 활성 제제의 제어 수송
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US6342533B1 (en) 1998-12-01 2002-01-29 Sepracor, Inc. Derivatives of (−)-venlafaxine and methods of preparing and using the same
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6797283B1 (en) 1998-12-23 2004-09-28 Alza Corporation Gastric retention dosage form having multiple layers
US6734213B2 (en) 1999-01-20 2004-05-11 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6855820B2 (en) * 1999-01-20 2005-02-15 Smithkline Beecham Corporation Pharmaceutically active morpholinol
US6638727B1 (en) * 1999-01-26 2003-10-28 Cytyc Health Corporation Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
DE19906974C2 (de) * 1999-02-19 2003-10-09 Lohmann Therapie Syst Lts Verwendung von Desoxypeganin zur Behandlung des Alkoholismus
US6337328B1 (en) 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
EP1181015A2 (en) 1999-03-01 2002-02-27 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
US6410052B1 (en) 1999-03-30 2002-06-25 Purdue Research Foundation Tea catechins in sustained release formulations as cancer specific proliferation inhibitors
EP1165487A1 (en) * 1999-04-06 2002-01-02 Sepracor Inc. Derivatives of venlafaxine and methods of preparing and using the same
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
DE60040979D1 (de) 1999-05-07 2009-01-15 Wockhardt Ltd (s)-benzochinolizincarbonsäuren und ihre verwendung als antibakterielle mittel
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
CA2383785C (en) 1999-09-03 2009-02-17 Eli Lilly And Company Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
US6491683B1 (en) 1999-09-07 2002-12-10 Alza Corporation Osmotic dosage form composed of an extruded polymer tube form
CO5210862A1 (es) 1999-09-15 2002-10-30 Alza Corp Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AR028299A1 (es) 1999-09-17 2003-05-07 Novartis Ag Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
US6638263B1 (en) 1999-10-12 2003-10-28 Durect Corporation Regulation of drug delivery through flow diversion
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
EP1239840B1 (en) * 1999-12-09 2005-04-06 Alza Corporation Antiviral medication
US7182953B2 (en) * 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
SK287105B6 (sk) 1999-12-20 2009-12-07 Schering Corporation Dvojvrstvový orálny dávkový prostriedok s predĺženým uvoľňovaním
AU2277101A (en) * 1999-12-20 2001-07-03 Schering Corporation Stable extended release oral dosage composition
US6491949B2 (en) 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6432446B2 (en) 2000-02-03 2002-08-13 Bridge Pharma, Inc. Non-arrhythmogenic metabolite of oxybutynin
US7405223B2 (en) 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
CN100558407C (zh) * 2000-02-04 2009-11-11 柳署弘 制备含有胆汁酸的澄清水溶液剂型
PL357158A1 (en) 2000-02-08 2004-07-12 Euro-Celtique, S.A. Controlled-release compositions containing opioid agonist and antagonist
PT1255547E (pt) 2000-02-08 2008-11-24 Euro Celtique Sa Composições de libertação controlada contendo agonistas e antagonistas opióides
US6616652B1 (en) 2000-02-15 2003-09-09 Microsolutions, Inc. Osmotic pump delivery system with pre-hydrated membrane(s) and/or primable catheter
US6464688B1 (en) 2000-02-15 2002-10-15 Microsolutions, Inc. Osmotic pump delivery system with flexible drug compartment
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
KR20020075801A (ko) 2000-02-18 2002-10-05 씨브이 쎄러퓨틱스, 인코포레이티드 울혈성 심부전 치료의 부분적 지방산 산화 방지제
WO2001062979A2 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Dentification of partial agonists of the a2a adenosine receptor
US6582441B1 (en) 2000-02-24 2003-06-24 Advanced Bionics Corporation Surgical insertion tool
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
US6569152B2 (en) * 2000-03-21 2003-05-27 Farrington Pharmaceuticals, Llc Sustained release delivery systems for solutes
JP2003528918A (ja) * 2000-03-31 2003-09-30 セルジーン コーポレイション シクロオキシゲナーゼ−２活性の阻害
US6544646B2 (en) 2000-04-27 2003-04-08 Verion Inc. Zero order release and temperature-controlled microcapsules and process for the preparation thereof
US7259152B2 (en) 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
CA2423431A1 (en) * 2000-10-06 2002-04-11 Durect Corporation Devices and methods for management of inflammation
CA2427815C (en) 2000-10-30 2007-07-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
AU2002230830A1 (en) 2000-11-03 2002-05-15 Andrx Labs, Llc Controlled release metformin compositions
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US6919327B2 (en) * 2000-11-17 2005-07-19 Pharmacyclics, Inc. Texaphyrin coordination compounds and uses thereof
US20030195706A1 (en) * 2000-11-20 2003-10-16 Michael Korenberg Method for classifying genetic data
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
AU2002219793A1 (en) * 2000-11-29 2002-06-11 Durect Corporation Devices and methods for controlled delivery from a drug delivery device
EP1353672B1 (en) * 2000-11-30 2007-10-03 The Children's Medical Center Corporation Synthesis of 4-amino-thalidomide enantiomers
AU2141202A (en) 2000-12-05 2002-06-18 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
AU2002239508B9 (en) 2000-12-07 2005-09-08 Gilead Palo Alto, Inc. Substituted 1, 3, 5-triazines and pyrimidines as ABCA-1 elevating compounds against coronary artery disease or atherosclerosis
US20030167524A1 (en) * 2000-12-19 2003-09-04 Rooijen Gijs Van Methods for the production of multimeric protein complexes, and related compositions
US20060064140A1 (en) * 2001-01-30 2006-03-23 Whitehurst Todd K Methods and systems for stimulating a trigeminal nerve to treat a psychiatric disorder
US20050143789A1 (en) * 2001-01-30 2005-06-30 Whitehurst Todd K. Methods and systems for stimulating a peripheral nerve to treat chronic pain
US7493172B2 (en) * 2001-01-30 2009-02-17 Boston Scientific Neuromodulation Corp. Methods and systems for stimulating a nerve originating in an upper cervical spine area to treat a medical condition
IN190699B (nl) 2001-02-02 2003-08-16 Sun Pharmaceutical Ind Ltd
JP4220243B2 (ja) * 2001-02-12 2009-02-04 ワイス Ｏ−デスメチル−ベンラファキシンの新規コハク酸塩
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
JP2004535166A (ja) 2001-03-22 2004-11-25 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
KR20030096292A (ko) 2001-03-27 2003-12-24 덴드레온 샌 디에고 엘엘씨 트랜스막 세린 프로테아제 9를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US6632217B2 (en) 2001-04-19 2003-10-14 Microsolutions, Inc. Implantable osmotic pump
US6964966B2 (en) * 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
WO2002092060A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
EP1539942A4 (en) 2001-05-14 2005-10-19 Dendreon Corp A TRANSMEMBRANE SERINE PROTEASE 10 CODING NUCLEIC ACID MOLECULES, THE POLYPEPTIDE CODED AND METHOD THEREOF
EP1404310A4 (en) * 2001-06-11 2005-01-12 Xenoport Inc ORAL ADMINISTRATIVE DOSAGE FORMS OF GABA ANALOG PRODRUGS WITH REDUCED TOXICITY
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
JP2005501013A (ja) * 2001-06-11 2005-01-13 ゼノポート，インコーポレイテッド Ｇａｂａ類似体の全身濃度が持続するアミノ酸コンジュゲート
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US20040180087A1 (en) * 2001-06-21 2004-09-16 Boyong Li Stable controlled release pharmaceutical compositions containing pravastatin
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system
US7034059B2 (en) * 2001-07-02 2006-04-25 Sepracor Inc. Methods of using norfluoxetine
AU2002346065A1 (en) * 2001-07-05 2003-01-21 Marantech Holding, Llc Methods of using electron active compounds for managing conditions afflicting mammals
BR0210855A (pt) 2001-07-06 2006-10-24 Penwest Pharmaceuticals Compan Método de fabricação de formulações de liberação prolongada
ES2284888T3 (es) * 2001-07-06 2007-11-16 Endo Pharmaceuticals Inc. Administracion oral de 6-hidroxi-oximorfona utilizada como analgesico.
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
US7713946B2 (en) * 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US7157440B2 (en) * 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
NZ530971A (en) 2001-08-06 2004-08-27 Euro Celtique S Oral dosage forms comprising an opioid agonist with releasable and sequestered opioid antagonists
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1283025A1 (de) * 2001-08-10 2003-02-12 Stöckert Instrumente GmbH Ballonokklusionsvorrichtung
US20030087963A1 (en) 2001-09-13 2003-05-08 Senanayake Chris H. Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
NZ532568A (en) * 2001-09-28 2005-07-29 Mcneil Ppc Inc Modified release dosage forms
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
JP4350517B2 (ja) 2001-11-09 2009-10-21 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニスト
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US7157493B2 (en) * 2001-11-28 2007-01-02 Nashai Biotech, Llc Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate and mixtures thereof
WO2003049673A2 (en) 2001-12-05 2003-06-19 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of sympathetic tone
US20030125714A1 (en) * 2001-12-18 2003-07-03 Edgren David Emil Dosage form for time-varying patterns of drug delivery
US20030198619A1 (en) * 2001-12-19 2003-10-23 Dong Liang C. Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
AU2002357930B2 (en) * 2001-12-19 2007-06-28 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents
US20040009953A1 (en) * 2002-01-10 2004-01-15 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
US20030181416A1 (en) * 2002-01-10 2003-09-25 Comper Wayne D. Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof
EP1474144B1 (en) 2002-02-01 2008-08-06 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US20030175346A1 (en) * 2002-02-01 2003-09-18 Anne Billotte Osmotic delivery system
US20030161882A1 (en) * 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
EP1472225B1 (en) 2002-02-01 2010-04-28 Euro-Celtique S.A. 2-piperazine-pyridines useful for treating pain
US8133501B2 (en) 2002-02-08 2012-03-13 Boston Scientific Scimed, Inc. Implantable or insertable medical devices for controlled drug delivery
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
WO2003101392A2 (en) * 2002-05-31 2003-12-11 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
CN101392012A (zh) 2002-02-19 2009-03-25 Cv医药有限公司 A1腺苷受体的部分和全促效药
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
EP1494998A2 (en) 2002-03-01 2005-01-12 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
KR101191254B1 (ko) * 2002-03-11 2012-10-16 알콘, 인코퍼레이티드 이식 가능한 약물 전달 시스템
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
CA2481236A1 (en) * 2002-03-29 2003-10-09 Alza Corporation Volume efficient controlled release dosage form
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
US20050245556A1 (en) 2002-04-05 2005-11-03 Bianca Brogmann Pharmaceutical preparation containing oxycodone and naloxone
US20040005358A1 (en) * 2002-04-23 2004-01-08 Slugg Peter H. Modified-release vasopeptidase inhibitor formulation, combinations and method
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20030224051A1 (en) * 2002-05-31 2003-12-04 Fink Tracy A. Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone
ES2320435T3 (es) * 2002-04-29 2009-05-22 Alza Corporation Metodo y formas de dosificacion para la administracion controlada de oxicodona.
US7470267B2 (en) * 2002-05-01 2008-12-30 Microlin, Llc Fluid delivery device having an electrochemical pump with an anionic exchange membrane and associated method
US7896867B2 (en) * 2002-05-01 2011-03-01 Microlin, Llc Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
US20060116663A1 (en) * 2002-05-01 2006-06-01 Joshi Ashok V Electro-osmotic fluid delivery device and method
US7458965B2 (en) * 2002-05-01 2008-12-02 Microlin, Llc Fluid delivery device having an electrochemical pump with an ion-exchange membrane and associated method
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
SI1505973T1 (sl) 2002-05-17 2010-06-30 Celgene Corp Kombinacija za zdravljenje multiplega mieloma
US7393862B2 (en) * 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7323479B2 (en) * 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
US7968569B2 (en) * 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
CN1668296A (zh) * 2002-05-17 2005-09-14 细胞基因公司 使用选择性细胞因子抑制性药物用于治疗和控制癌症和其它疾病的方法及组合物
USRE48890E1 (en) 2002-05-17 2022-01-11 Celgene Corporation Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
BR0311161A (pt) 2002-05-21 2005-03-29 Cv Therapeutics Inc Método de tratamento de diabetes
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
AU2003241537A1 (en) * 2002-05-23 2003-12-12 Andrx Corporation Biguanide formulations
US7151961B1 (en) * 2002-05-24 2006-12-19 Advanced Bionics Corporation Treatment of movement disorders by brain stimulation
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
ES2473581T3 (es) * 2002-05-31 2014-07-07 Proteotech Inc. Compuestos, composiciones y métodos para el tratamiento de amiloidosis y sinucleinopat�as tales como la enfermedad de Alzheimer, la diabetes de tipo 2 y la enfermedad de Parkinson
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US6900203B2 (en) 2002-06-19 2005-05-31 Polium Technologies, Inc. Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them
IL165383A0 (en) 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
US20050175690A1 (en) * 2003-12-29 2005-08-11 David Edgren Novel drug compositions and dosage forms
NZ537492A (en) * 2002-06-28 2007-10-26 Alza Corp Oral dosage form comprising a liquid active agent formulation and controlling release thereof by an expandable osmotic composition
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
GEP20074270B (en) 2002-07-23 2007-12-25 Univ Michigan Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies
CA2493458A1 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
MXPA05001184A (es) * 2002-07-29 2005-09-12 Johnson & Johnson Formulaciones y formas de dosificacion para administracion controlada de topiramato.
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
CN1671399A (zh) * 2002-07-29 2005-09-21 Cv医药有限公司 利用a2a受体激动剂的心肌灌注显像
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
US7254449B2 (en) * 2002-07-31 2007-08-07 Advanced Bionics Corp Systems and methods for providing power to one or more implantable devices
ES2358896T3 (es) 2002-08-15 2011-05-16 Euro-Celtique S.A. Composiciones farmacéuticas que comprenden un analgésico opioide.
US20040132806A1 (en) 2002-09-03 2004-07-08 Jackie Butler Pravastatin pharmaceutical formulations and methods of their use
US20060009739A1 (en) * 2002-09-06 2006-01-12 Durect Corporation Implantable flow regulator with failsafe mode and reserve drug supply
JP2006502158A (ja) 2002-09-06 2006-01-19 デュレクト コーポレーション グルタメート媒介神経伝達のモジュレーターの内耳への送達
US20050048119A1 (en) * 2002-09-20 2005-03-03 Avinash Nangia Controlled release composition with semi-permeable membrane and poloxamer flux enhancer
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
ES2529180T3 (es) 2002-09-20 2015-02-17 Andrx Labs Llc Formulación multietapa que contiene una biguanida y un derivado de tiazolidinodiona
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP2422773A3 (en) 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
EP1543010B1 (en) 2002-09-25 2007-04-25 Euro-Celtique S.A. N-substituted hydromorphones and the use thereof
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
EP1549141A4 (en) * 2002-09-27 2008-06-25 Bioenvision Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES USING CLOFARABIN
WO2004028463A2 (en) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methods and compositions for the treatment of lupus using clofarabine
JP2006505620A (ja) * 2002-10-07 2006-02-16 レイディオアールエックス インコーポレイテッド Ｘ−ニトロ化合物、それらの医薬組成物及びそれらの使用
JP2006507357A (ja) * 2002-10-11 2006-03-02 プロテオテック・インコーポレイテッド プロシアニジンｂ２の単離、精製および合成ならびにその使用
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US8404716B2 (en) 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
BR0315316A (pt) * 2002-10-15 2005-08-16 Celgene Corp Métodos de tratar, prevenir ou controlar uma sìndrome mielodisplásica, e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária, e, kit
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
EP1900369A1 (en) 2002-10-15 2008-03-19 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP1556017A1 (en) * 2002-10-31 2005-07-27 ALZA Corporation Dosage form providing ascending release of liquid formulation
EP1556000A1 (en) * 2002-10-31 2005-07-27 Alza Corporation Pharmaceutical formulation providing an increased biovailability of hydrophobic drugs
WO2004041203A2 (en) * 2002-11-04 2004-05-21 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
KR100923173B1 (ko) 2002-11-06 2009-10-22 셀진 코포레이션 암 및 다른 질환의 치료 및 관리를 위한 선택적 시토킨억제 약물의 사용 방법 및 그 조성물
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
AU2003294311B8 (en) * 2002-11-18 2008-06-05 Celgene Corporation Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
MXPA05005161A (es) * 2002-11-18 2005-07-22 Celgene Corp Metodos de utilizacion y composiciones que comprenden (-)3- (3, 4-dimetoxi- fenil)-3 -(1-oxo -1, 3-dihidro- isoindol- 2-il)- propionamida.
EP1594521A4 (en) * 2002-11-25 2008-01-09 Attenuon Llc PEPTIDES THAT LIMIT ANGIOGENESIS, CELL WALKING, CELL INVASION AND CELL PROLIFERATION, AND THEIR COMPOSITIONS AND USES
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
US8286834B2 (en) * 2002-12-09 2012-10-16 Jeffrey Lewis Powers Skin treatment dispenser and method of manufacture
US20040111071A1 (en) * 2002-12-09 2004-06-10 Jeffrey Lewis Powers Portable device for dispensing hand treatments
WO2004052360A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
WO2004053192A1 (en) * 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
CA2801155A1 (en) 2002-12-13 2004-07-01 Durect Corporation Oral drug delivery system
CA2508948A1 (en) * 2002-12-16 2004-07-15 Halozyme, Inc. Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
CA2510261A1 (en) * 2002-12-17 2004-07-01 Abbott Gmbh & Co. Kg Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
US20070077301A1 (en) * 2002-12-23 2007-04-05 Meyer Glenn A Venlafaxine osmotic device formulation
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
EP2339328A3 (en) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of celecoxib
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
JP2006522016A (ja) * 2003-01-14 2006-09-28 アルザ・コーポレーシヨン 改変された粘度の層を用いる方法および投薬形態物
JP2006515891A (ja) 2003-01-17 2006-06-08 シーブイ・セラピューティクス・インコーポレイテッド 循環器疾患の処置に有効な置換ヘテロ環化合物
ZA200504940B (en) * 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
US20040197407A1 (en) * 2003-02-11 2004-10-07 Ramkumar Subramanian Methods and dosage forms with modified layer geometry
KR20050101208A (ko) 2003-02-13 2005-10-20 반유 세이야꾸 가부시끼가이샤 신규한 2-피리딘 카복사미드 유도체
JP4923182B2 (ja) 2003-02-28 2012-04-25 マクニール−ピーピーシー・インコーポレーテツド セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
ATE448323T1 (de) 2003-03-05 2009-11-15 Halozyme Inc Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
WO2004089289A2 (en) * 2003-03-31 2004-10-21 Xenoport, Inc. Treating or preventing hot flashes using prodrugs of gaba analogs
WO2004091278A2 (en) * 2003-04-11 2004-10-28 Transform Pharmaceuticals, Inc. Gabapentin compositions
WO2004091502A2 (en) 2003-04-11 2004-10-28 Ptc Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US20070083240A1 (en) * 2003-05-08 2007-04-12 Peterson David K L Methods and systems for applying stimulation and sensing one or more indicators of cardiac activity with an implantable stimulator
WO2005016241A2 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US8029822B2 (en) * 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
US7186863B2 (en) * 2003-05-23 2007-03-06 Transform Pharmaceuticals, Inc. Sertraline compositions
JP2007502865A (ja) * 2003-05-23 2007-02-15 ブリッジ ファーマ、インコーポレイテッド 平滑筋鎮痙剤
EP1633310A4 (en) * 2003-05-27 2006-10-18 Attenuon Llc THIOTUNGSTATE ANALOGUES AND USES THEREOF
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
US20090227647A1 (en) * 2008-03-05 2009-09-10 Thomas Lake Compounds, Compositions and Methods for the Treatment of Islet Amyloid Polypeptide (IAPP) Accumulation in Diabetes
US7438903B2 (en) * 2003-06-06 2008-10-21 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
TWI287010B (en) * 2003-06-12 2007-09-21 Euro Celtique Sa Therapeutic agents useful for treating pain
EP1643946A2 (en) * 2003-06-20 2006-04-12 Viral Genomix, Inc. Compositions for and methods for treating hiv
US7145125B2 (en) 2003-06-23 2006-12-05 Advanced Optical Technologies, Llc Integrating chamber cone light using LED sources
EP2112920B1 (en) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
ATE423111T1 (de) * 2003-07-03 2009-03-15 Euro Celtique Sa 2-pyridin alkyne derivaten und ihre verwendung für die schmerzbehandlung
WO2005004882A1 (en) * 2003-07-09 2005-01-20 Monash University Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
BRPI0412805A (pt) * 2003-07-23 2006-09-26 Synta Pharmaceuticals Corp método para modular canais de ìon de cálcio ativado por liberação de ìon de cálcio
BRPI0412248B1 (pt) * 2003-07-24 2018-12-26 Euro Celtique Sa agentes terapêuticos úteis para tratar dor, composição farmacêutica, uso, kit e processo para preparação da dita composição
US20050020692A1 (en) * 2003-07-24 2005-01-27 Ciofalo Vincent B. Treatment of heaves
EP1867644B1 (en) 2003-07-24 2009-05-20 Euro-Celtique S.A. Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
CN101914088A (zh) * 2003-07-24 2010-12-15 尤罗塞尔蒂克股份有限公司 哌啶化合物和含有它们的药物组合物
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
AU2004261277A1 (en) * 2003-07-31 2005-02-10 Alza Corporation Permeation-Resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation
US20090317476A1 (en) * 2003-07-31 2009-12-24 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
PL1942106T3 (pl) * 2003-08-01 2012-02-29 Euro Celtique Sa Środki lecznicze użyteczne do leczenia bólu
CA2534920A1 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
PT1660440E (pt) * 2003-08-20 2012-05-15 Xenoport Inc Pró-fármacos de aciloxialquilcarbamato, métodos de síntese e utilização
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
WO2005020957A2 (en) * 2003-08-22 2005-03-10 Alza Corporation Stepwise delivery of topiramate over prolonged period of time
CA2536061A1 (en) * 2003-08-22 2005-03-17 Edward J. Ellis Polymeric systems for controlled drug therapy
GB0320020D0 (en) 2003-08-27 2003-10-01 Mw Encap Ltd Improved formulation for providing an enteric coating material
EP1701697A2 (en) * 2003-09-02 2006-09-20 ALZA Corporation Novel drug compositions and dosage forms of topiramate
MXPA06002443A (es) * 2003-09-03 2006-08-31 Agi Therapeutics Ltd Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
ES2290560T3 (es) * 2003-09-04 2008-02-16 Wockhardt Limited Sal de arginina del acido benzoquinolizina-2-carboxilico tetrahidratada.
UA83504C2 (en) * 2003-09-04 2008-07-25 Селджин Корпорейшн Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
WO2005023204A2 (en) * 2003-09-09 2005-03-17 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
EP1670451A4 (en) 2003-09-11 2009-10-21 Xenoport Inc TREATMENT AND / OR PREVENTION OF URINARY INCONTINENCE AND PROMOTERS OF GABA ANALOGS
WO2005027850A2 (en) * 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
WO2005027853A2 (en) * 2003-09-19 2005-03-31 University Of Louisville Research Foundation Inc Method for treating snoring and sleep apnea with leukotriene antagonists
CN1863790A (zh) * 2003-09-22 2006-11-15 欧洲凯尔特公司 用于治疗疼痛的治疗药
CN1856489A (zh) * 2003-09-22 2006-11-01 欧洲凯尔特公司 用于治疗疼痛的苯甲酰胺化合物
PL1663229T3 (pl) 2003-09-25 2010-09-30 Euro Celtique Sa Farmaceutyczne kombinacje hydrokodonu i naltreksonu
CA2540045A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Dosage form for controlled release of an active agent formulation
KR20060095765A (ko) * 2003-09-26 2006-09-01 알자 코포레이션 알프라졸람의 제어 송달용 삼투성 제형
US20050186273A1 (en) * 2003-09-26 2005-08-25 Si-Hong Yum Controlled release dosage form including a banded engine
CA2540047A1 (en) 2003-09-26 2005-04-07 Alza Corporation Oros push-stick for controlled delivery of active agents
NZ546148A (en) 2003-09-26 2009-05-31 Alza Corp Drug coating providing high drug loading and methods for providing the same
AU2004275835B2 (en) 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
WO2005030181A1 (en) * 2003-09-26 2005-04-07 Alza Corporation Controlled release formulations of opioid and nonopioid analgesics
CN1867322B (zh) * 2003-10-14 2014-06-25 什诺波特有限公司 结晶形式的γ-氨基丁酸类似物
US7612096B2 (en) * 2003-10-23 2009-11-03 Celgene Corporation Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US20050118246A1 (en) * 2003-10-31 2005-06-02 Wong Patrick S. Dosage forms and layered deposition processes for fabricating dosage forms
JP2007509972A (ja) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン レボドパ及びカルビドパの投与
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
US20050113410A1 (en) * 2003-11-03 2005-05-26 Mark Tawa Pharmaceutical salts of zafirlukast
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
CA2545128C (en) * 2003-11-06 2010-01-12 Celgene Corporation Methods and compositions using thalidomide for the treatment and management of cancers and other diseases
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
MXPA06005462A (es) * 2003-11-14 2006-12-15 Johnson & Johnson Liberacion controlada de topiramato en formas de dosificacion liquida.
US7470435B2 (en) * 2003-11-17 2008-12-30 Andrx Pharmaceuticals, Llc Extended release venlafaxine formulation
AU2004293443A1 (en) 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc. Indazole Compounds and methods of use thereof as protein kinase inhibitors
US7829552B2 (en) 2003-11-19 2010-11-09 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
US20050175695A1 (en) * 2003-11-25 2005-08-11 Catherine Castan Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1689787A2 (en) * 2003-11-28 2006-08-16 Eastman Chemical Company Cellulose interpolymers and method of oxidation
US20050129764A1 (en) * 2003-12-11 2005-06-16 Vergez Juan A. Osmotic device containing licofelone
EP2343073A3 (en) 2003-12-11 2011-10-12 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
US7769461B2 (en) * 2003-12-19 2010-08-03 Boston Scientific Neuromodulation Corporation Skull-mounted electrical stimulation system and method for treating patients
KR20060123493A (ko) * 2003-12-23 2006-12-01 알자 코포레이션 제어된 전달을 위한 약물 조성물의 용해도를 증가시키는방법 및 제형
TW200522944A (en) 2003-12-23 2005-07-16 Lilly Co Eli CB1 modulator compounds
CA2553160C (en) * 2003-12-29 2010-09-28 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
WO2005065648A2 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc., Novel drug compositions and dosage forms of topiramate
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
PL1727801T3 (pl) * 2003-12-30 2009-08-31 Euro Celtique Sa Piperazyny użyteczne do leczenia bólu
US8138204B2 (en) * 2004-01-07 2012-03-20 Aryx Therapeutics, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
AU2005205531B2 (en) 2004-01-07 2011-03-17 Renexxion, Llc Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8524736B2 (en) 2004-01-07 2013-09-03 Armetheon, Inc. Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
AU2005209201B2 (en) 2004-01-20 2010-06-03 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20060003001A1 (en) * 2004-02-11 2006-01-05 John Devane Chronotherapeutic compositions and methods of their use
CA2555811A1 (en) 2004-02-18 2005-08-25 Gpc Biotech Ag Methods for treating resistant or refractory tumors
EP1729784A1 (en) * 2004-02-23 2006-12-13 Attenuon, LLC Formulations of thiomolybdate or thiotungstate compounds and uses thereof
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
US7612071B2 (en) 2004-03-12 2009-11-03 Syntrix Biosystems, Inc. Compositions and methods employing aminopterin
US20050209295A1 (en) * 2004-03-16 2005-09-22 Kohn Leonard D Methimazole derivatives and tautomeric cyclic thiones to inhibit cell adhesion
US20100004304A1 (en) * 2004-03-16 2010-01-07 Kohn Leonard D Methods and compositions for the treatment of malignant melanoma, breast, prostate, colon, papillary thyroid and pancreatic cancer
US7928132B2 (en) * 2004-08-06 2011-04-19 Ohio University Methods for the amelioration of episodes of acute or chronic ulcerative colitis
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
KR101224262B1 (ko) 2004-03-22 2013-01-21 셀진 코포레이션 면역조절 화합물을 포함하는 피부 질환 또는 장애의 치료및 관리용 조성물 및 이의 사용 방법
WO2005092065A2 (en) * 2004-03-25 2005-10-06 Transform Pharmaceuticals, Inc. Novel tricyclic compounds and related methods of treatment
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
CN100522960C (zh) * 2004-04-08 2009-08-05 惠氏公司 作为黄体酮受体调节剂的硫代酰胺衍生物
AU2004319758A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
CA2563207A1 (en) * 2004-04-14 2005-11-24 Celgene Corporation Use of selective cytokine inhibitory drugs in myelodysplastic syndromes
KR20070007945A (ko) * 2004-04-23 2007-01-16 셀진 코포레이션 폐 고혈압증의 치료 및 관리를 위한 ｐｄｅ4 조절인자의사용 방법 및 그를 포함하는 조성물
MXPA06012403A (es) 2004-04-27 2007-01-17 Wyeth Corp Purificacion de moduladores de receptor progesterona.
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7351739B2 (en) * 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US7803366B2 (en) * 2004-05-07 2010-09-28 Nbty, Inc. Methods and compositions that enhance bioavailability of coenzyme-Q10
US20060185357A1 (en) * 2004-05-07 2006-08-24 Kovacevich Ian D Independently drawing and tensioning lines with bi-directional rotary device having two spools
JP2008506366A (ja) * 2004-05-14 2008-03-06 レセプター バイオロジックス インコーポレイテッド 細胞表面受容体アイソフォームならびにその同定および使用方法
WO2005115383A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
EP1758452B1 (en) * 2004-05-28 2017-01-25 Human Biomolecular Research Institute Metabolically stable analgesics and pain medications
US20050267555A1 (en) * 2004-05-28 2005-12-01 Marnfeldt Goran N Engagement tool for implantable medical devices
WO2005117585A1 (en) 2004-05-28 2005-12-15 Transform Pharmaceuticals, Inc. Mixed co-crystals and pharmaceutical compositions comprising the same
US20080138282A1 (en) * 2004-06-03 2008-06-12 The Trustees Of Columbia University In The City Of New York Radiolabeled Arylsulfonyl Compounds and Uses Thereof
BRPI0510776A (pt) * 2004-06-04 2007-11-20 Xenoport Inc pró-fármacos de levodopa, e suas composições e usos
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
WO2005123039A1 (en) 2004-06-12 2005-12-29 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
US20050276848A1 (en) * 2004-06-15 2005-12-15 Nilobon Podhipleux Sustained release neutralized divalproex sodium
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
JP5017103B2 (ja) * 2004-06-17 2012-09-05 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 薬剤共結晶組成物および関連した使用方法
EP1771435A4 (en) * 2004-06-19 2008-02-13 Human Biomolecular Res Inst MODULATORS OF NEUROTRANSMITTERS OF THE CENTRAL NERVOUS SYSTEM
US20050287185A1 (en) * 2004-06-23 2005-12-29 David Wong Extended release oxybutynin formulation
EP1761265A2 (en) * 2004-06-28 2007-03-14 ALZA Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
WO2006007351A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Squeeze controlled oral dosage form
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20080027513A1 (en) * 2004-07-09 2008-01-31 Advanced Bionics Corporation Systems And Methods For Using A Butterfly Coil To Communicate With Or Transfer Power To An Implantable Medical Device
WO2006017351A1 (en) * 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
DK1781596T3 (da) * 2004-07-12 2009-01-19 Xenoport Inc Aminosyreafledte profarmaka af propofolsammensætninger og anvendelser deraf
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
WO2006012536A2 (en) 2004-07-22 2006-02-02 Ritter Andrew J Methods and compositions for treating lactose intolerance
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
JP2008516890A (ja) * 2004-08-06 2008-05-22 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なフェノフィブラート製剤および関連治療方法
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
EP1786414A4 (en) * 2004-08-06 2008-04-09 Transform Pharmaceuticals Inc NEW PHARMACEUTICAL STATIN COMPOSITIONS AND RELEVANT TREATMENT PROCEDURES
EP2431026A1 (en) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
BRPI0513846A (pt) * 2004-08-13 2008-05-20 Boehringer Ingelheim Int formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo
US8452407B2 (en) * 2004-08-16 2013-05-28 Boston Scientific Neuromodulation Corporation Methods for treating gastrointestinal disorders
CA2577583A1 (en) * 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION
AU2005279961B2 (en) * 2004-08-30 2010-05-13 Seo Hong Yoo Neuroprotective effect of solubilized UDCA in focal ischemic model
US20120277839A1 (en) 2004-09-08 2012-11-01 Kramer Jeffery M Selective stimulation to modulate the sympathetic nervous system
US9205261B2 (en) 2004-09-08 2015-12-08 The Board Of Trustees Of The Leland Stanford Junior University Neurostimulation methods and systems
US7450993B2 (en) * 2004-09-08 2008-11-11 Spinal Modulation, Inc. Methods for selective stimulation of a ganglion
NZ554545A (en) 2004-09-17 2010-10-29 Whitehead Inst Of Biomedical R Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
US7709518B2 (en) * 2004-09-21 2010-05-04 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
NZ554485A (en) 2004-10-15 2010-12-24 Gilead Palo Alto Inc Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists
WO2006044771A2 (en) 2004-10-15 2006-04-27 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
WO2006044856A2 (en) * 2004-10-20 2006-04-27 Cv Therapeuitics, Inc. Use of a2a adenosine receptor agonists
WO2006046112A2 (en) * 2004-10-25 2006-05-04 Ranbaxy Laboratories Limited Ketolide derivatives as antibacterial agents
MX2007005040A (es) * 2004-10-28 2007-06-19 Celgene Corp Metodos y composiciones usando moduladores de pde4 para el tratamiento y manejo de lesion al sistema nervioso central.
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
RU2398773C2 (ru) 2004-11-02 2010-09-10 Баниу Фармасьютикал Ко., Лтд. Арилоксизамещенное производное бензимидазола
WO2006050472A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2006050471A2 (en) * 2004-11-03 2006-05-11 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
NZ554737A (en) 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
US9358393B1 (en) 2004-11-09 2016-06-07 Andres M. Lozano Stimulation methods and systems for treating an auditory dysfunction
WO2006053184A2 (en) * 2004-11-10 2006-05-18 The Trustees Of Columbia University In The City Of New York Methods for treating or preventing a vascular disease
WO2006055760A1 (en) 2004-11-18 2006-05-26 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US20100016400A1 (en) * 2004-11-19 2010-01-21 Naresh Kumar Azabicyclic muscarinic receptor antagonists
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US7483746B2 (en) * 2004-12-06 2009-01-27 Boston Scientific Neuromodulation Corp. Stimulation of the stomach in response to sensed parameters to treat obesity
WO2006065792A2 (en) * 2004-12-13 2006-06-22 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using cannabinoid analogs
US20060128794A1 (en) 2004-12-13 2006-06-15 Indevus Pharmaceuticals, Inc. Treatment of interstitial cystitis using (6aR,10aR)-delta8-tetrahydrocannabinol-11-OIC acids
EP1831235B1 (en) * 2004-12-16 2013-02-20 The Regents of The University of California Lung-targeted drugs
CA2589529C (en) 2004-12-17 2013-09-10 Anadys Pharmaceuticals, Inc. 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo [4,5-d]pyrimidin-2-one compounds and prodrugs thereof
US20070038264A1 (en) * 2004-12-21 2007-02-15 Jaax Kristen N Methods and systems for treating autism
US20060161217A1 (en) * 2004-12-21 2006-07-20 Jaax Kristen N Methods and systems for treating obesity
US9095713B2 (en) * 2004-12-21 2015-08-04 Allison M. Foster Methods and systems for treating autism by decreasing neural activity within the brain
US9327069B2 (en) 2004-12-21 2016-05-03 Boston Scientific Neuromodulation Corporation Methods and systems for treating a medical condition by promoting neural remodeling within the brain
US8515541B1 (en) 2004-12-22 2013-08-20 Boston Scientific Neuromodulation Corporation Methods and systems for treating post-stroke disorders
US9352145B2 (en) * 2004-12-22 2016-05-31 Boston Scientific Neuromodulation Corporation Methods and systems for treating a psychotic disorder
CA2586410A1 (en) * 2004-12-23 2006-07-06 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
EP2096107A1 (en) 2004-12-23 2009-09-02 GPC Biotech AG Derivatives of squaric acid with anti-proliferative activity
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
NZ556546A (en) 2005-01-07 2011-02-25 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
CA2595855C (en) * 2005-01-25 2017-07-04 Synta Pharmaceuticals Corp. Pyrazine compounds for inflammation and immune-related uses
WO2006081569A2 (en) * 2005-01-27 2006-08-03 Alza Corporation Oral osmotic dosage form having a high flux membrane
AU2006208627B8 (en) * 2005-01-28 2009-08-13 Mundipharma Pty Limited Alcohol resistant dosage forms
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
EP1690540A1 (en) * 2005-02-15 2006-08-16 Neuro3D Composition comprising ocaperidone
US20060185665A1 (en) * 2005-02-22 2006-08-24 Bachinski Thomas J Sauna fireplace
US20060194724A1 (en) * 2005-02-25 2006-08-31 Whitehurst Todd K Methods and systems for nerve regeneration
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
US7312217B2 (en) 2005-03-11 2007-12-25 Syntrix Biosystems, Inc. Aminopterin dosage forms and methods for inflammatory disorders
US7853321B2 (en) 2005-03-14 2010-12-14 Boston Scientific Neuromodulation Corporation Stimulation of a stimulation site within the neck or head
US8423155B1 (en) 2005-03-14 2013-04-16 Boston Scientific Neuromodulation Corporation Methods and systems for facilitating stimulation of one or more stimulation sites
US20060206165A1 (en) * 2005-03-14 2006-09-14 Jaax Kristen N Occipital nerve stimulation to treat headaches and other conditions
US7848803B1 (en) 2005-03-14 2010-12-07 Boston Scientific Neuromodulation Corporation Methods and systems for facilitating stimulation of one or more stimulation sites
US7702385B2 (en) * 2005-11-16 2010-04-20 Boston Scientific Neuromodulation Corporation Electrode contact configurations for an implantable stimulator
WO2006102375A2 (en) 2005-03-21 2006-09-28 Metabolex, Inc. Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
EP1866319B1 (en) 2005-04-01 2011-11-23 The Regents of The University of California Phosphono-pent-2-en-1-yl nucleosides and analogs
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20060280790A1 (en) 2005-04-08 2006-12-14 Ju Tzuchi R Pharmaceutical formulations
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
US20060229261A1 (en) * 2005-04-12 2006-10-12 John Devane Acarbose methods and formulations for treating chronic constipation
EP1874782A1 (en) * 2005-04-15 2008-01-09 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
AR053713A1 (es) * 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
WO2006119365A2 (en) 2005-05-02 2006-11-09 Cold Spring Harbor Laboratory Composition and methods for cancer diagnosis utilizing the mir 17-92 cluster
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same
US20070041944A1 (en) * 2005-05-05 2007-02-22 The Trustees Of Columbia University In The City Of New York Treating tumors by ENH dislocation of ID proteins
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
RU2415858C2 (ru) 2005-06-16 2011-04-10 Си Ви Терапьютикс, Инк. Пролекарства антагонистов a2b рецептора аденозина
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
DE602006014694D1 (de) 2005-06-20 2010-07-15 Xenoport Inc Acyloxyalkylcarbamat-prodrugs von tranexansäure und anwendung
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
EP2474308A1 (en) 2005-06-27 2012-07-11 Valeant International (Barbados) SRL Pharmaceutical formulations containing bupropion hydrobromide
US7423045B2 (en) * 2005-06-28 2008-09-09 Cv Therapeutics, Inc. ABCA1 elevating compounds
EP1904030A2 (en) * 2005-06-29 2008-04-02 Alza Corporation Semi-permeable compositions providing reduced drying time for osmotic dosage forms
US8348930B2 (en) * 2005-07-01 2013-01-08 Microlin, Llc Fluid delivery device with a diffusion membrane and electrochemical pump
WO2007005961A2 (en) * 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US20070009573A1 (en) * 2005-07-07 2007-01-11 L N K International Method of forming immediate release dosage form
TWI279234B (en) * 2005-07-12 2007-04-21 Anchen Pharmaceuticals Taiwan Method for controlling lag time of in-situ passageway formation in osmotic delivery system
US20070025869A1 (en) * 2005-07-15 2007-02-01 Gordon John H Fluid Delivery Device
US20070021734A1 (en) * 2005-07-15 2007-01-25 Sai Bhavaraju Bioelectro-osmotic engine fluid delivery device
US20070023291A1 (en) * 2005-07-15 2007-02-01 Sai Bhavaraju Metal Trap
WO2007013929A1 (en) 2005-07-22 2007-02-01 Amgen Inc. Aniline sulfonamide derivatives and their uses
JP2009507774A (ja) * 2005-08-04 2009-02-26 アルザ・コーポレーシヨン 改良された性質を提供するポリマー混合物による半透過性膜を含んでなる浸透性用量形態物
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
EP1928450A2 (en) * 2005-08-26 2008-06-11 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20080274180A1 (en) * 2005-08-30 2008-11-06 Nicholas Piramal India Limited Extended Release Pharmaceutical Composition of Metformin and a Process for Producing It
UA91560C2 (ru) 2005-08-31 2010-08-10 Селджин Корпорэйшн Соединения ряда изоиндолимидов, их композиция и применение
EP1919909B1 (en) * 2005-08-31 2013-08-21 Armetheon, Inc. Synthetic methods and intermediates for stereoisomeric compounds useful for the treatment of gastrointestinal and central nervous system disorders
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US7684858B2 (en) * 2005-09-21 2010-03-23 Boston Scientific Neuromodulation Corporation Methods and systems for placing an implanted stimulator for stimulating tissue
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
EP1935890B1 (en) * 2005-09-30 2016-03-16 Msd K.K. 2-heteroaryl-substituted indole derivative
US20070190137A1 (en) * 2005-10-07 2007-08-16 Reyes Iran Osmotic dosage form with controlled release and fast release aspects
EP1943251B8 (en) * 2005-10-13 2011-03-23 Gilead Palo Alto, Inc. A1 adenosine receptor agonists
US20070092585A1 (en) * 2005-10-14 2007-04-26 Skinner Michael K Cancer chemotherapy compositions comprising PI3K pathways modulators and triptolide
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP1960382A1 (en) 2005-11-03 2008-08-27 ChemBridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
US20070104788A1 (en) 2005-11-10 2007-05-10 Seamus Mulligan Once-daily administration of central nervous system drugs
WO2007058776A2 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins
WO2007059010A2 (en) 2005-11-14 2007-05-24 Enterprise Partners Venture Capital Stem cell factor therapy for tissue injury
UA91250C2 (en) 2005-11-21 2010-07-12 Пердью Фарма Л.П. 4-oxadiazolyl-piperidine compounds and use thereof
US7729758B2 (en) 2005-11-30 2010-06-01 Boston Scientific Neuromodulation Corporation Magnetically coupled microstimulators
WO2007067495A2 (en) * 2005-12-05 2007-06-14 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
US7982066B2 (en) 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US8138361B2 (en) * 2005-12-28 2012-03-20 The Trustees Of The University Of Pennsylvania C-10 carbamates of taxanes
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
US7610100B2 (en) * 2005-12-30 2009-10-27 Boston Scientific Neuromodulation Corporation Methods and systems for treating osteoarthritis
US7835803B1 (en) 2006-01-17 2010-11-16 Boston Scientific Neuromodulation Corporation Lead assemblies with one or more switching networks
EP1983980A4 (en) * 2006-01-25 2010-05-05 Synta Pharmaceuticals Corp THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY
JP2009524683A (ja) 2006-01-25 2009-07-02 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のためのビニル−フェニル誘導体
TW200806290A (en) 2006-01-25 2008-02-01 Synta Pharmaceuticals Corp Substituted biaryl compounds for inflammation and immune-related uses
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
ES2403368T3 (es) * 2006-01-31 2013-05-17 Synta Pharmaceuticals Corporation Compuestos de piridilfenilo para la inflamación y usos inmunorrelacionados
JP5326156B2 (ja) 2006-02-03 2013-10-30 ギリアード サイエンシーズ， インコーポレイテッド Ａ２ａ−アデノシンレセプターアゴニストおよびその多形体の調製方法
MX2008009947A (es) * 2006-02-03 2008-10-20 Avanir Pharmaceuticals Composiciones farmaceuticas que comprenden dextrometorfano y quinidina para el tratamiento de depresion, ansiedad y trastornos neurodegenerativos.
WO2007090881A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Modified release formulation
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US20070196487A1 (en) * 2006-02-16 2007-08-23 Geerke Johan H Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US7518017B2 (en) 2006-02-17 2009-04-14 Idexx Laboratories Fenicol compounds and methods synthesizing 2-trifluoroacetamido-3-substituted propiophenone compounds
US20070201024A1 (en) * 2006-02-28 2007-08-30 Geerke Johan H Method and apparatus for semi-permeable membrane detection on osmotic tablets incorating near-infrared spectroscopy
ATE494782T1 (de) 2006-03-10 2011-01-15 Neurogen Corp Piperazinyl-oxoalkyl-tetrahydroisochinoline und verwandte analoga
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
CA2646438A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
DK2383271T3 (da) * 2006-03-13 2013-10-07 Kyorin Seiyaku Kk Aminoquinoloner som GSK-3-inhibitorer
US8175710B2 (en) * 2006-03-14 2012-05-08 Boston Scientific Neuromodulation Corporation Stimulator system with electrode array and the method of making the same
US20070219174A1 (en) * 2006-03-15 2007-09-20 Pharmacyclics, Inc. Methods of treating cancer using hypofractionated radiation and texaphyrins
WO2007126841A2 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
CN101453996B (zh) * 2006-04-03 2016-05-11 伊萨·奥迪迪 药物递送组合物
EP2015805A1 (en) * 2006-04-28 2009-01-21 Koninklijke Philips Electronics N.V. Osmotic pump with at least one chargeable material
US9011930B2 (en) * 2006-05-01 2015-04-21 Zycal Bioceuticals Healthcare Company, Inc. Nutritional supplement and use thereof
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2027087A2 (en) 2006-05-18 2009-02-25 MannKind Corporation Intracellular kinase inhibitors
US8058260B2 (en) * 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
EP2046393B1 (en) 2006-05-26 2014-02-12 Signature Therapeutics, Inc. Controlled release of phenolic opioids
TW200808695A (en) * 2006-06-08 2008-02-16 Amgen Inc Benzamide derivatives and uses related thereto
DE602007008237D1 (de) * 2006-06-08 2010-09-16 Amgen Inc Benzamidderivate und assoziierte verwendungen
KR20090031897A (ko) * 2006-06-12 2009-03-30 리셉터 바이오로직스 인크 전-세포 표면 수용체-특이적 치료제
PT2719378T (pt) 2006-06-19 2016-11-02 Alpharma Pharmaceuticals Llc Composições farmacêuticas
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
EP2038286B1 (en) 2006-06-22 2017-03-08 Anadys Pharmaceuticals, Inc. Pyrro[1,2-b]pyridazinone compounds
TWI418561B (zh) 2006-06-22 2013-12-11 Anadys Pharmaceuticals Inc ５-胺基-３-（３’-去氧-β-Ｄ-核糖呋喃糖基（ｒｉｂｏｆｕｒａｎｏｓｙｌ））-噻唑并〔４，５-ｄ〕嘧啶-２，７-二酮之前藥
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20080085915A1 (en) * 2006-06-23 2008-04-10 Cyrus Becker Compounds and methods for the treatment of gastrointestinal and central nervous system disorders
US8401654B1 (en) 2006-06-30 2013-03-19 Boston Scientific Neuromodulation Corporation Methods and systems for treating one or more effects of deafferentation
US8504163B1 (en) 2006-06-30 2013-08-06 Boston Scientific Neuromodulation Corporation Cranially mounted stimulation systems and methods
ES2579437T3 (es) 2006-07-05 2016-08-11 Catalyst Biosciences, Inc. Procedimientos de cribado de proteasas y proteasas identificadas por los mismos
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
JP5225991B2 (ja) 2006-07-18 2013-07-03 アナディス ファーマシューティカルズ インク チアゾロ［４，５−ｄ］ピリミジンのカーボネート及びカルバメートプロドラッグ
EP2049087A2 (en) * 2006-07-21 2009-04-22 LAB International SRL Hydrophilic abuse deterrent delivery system
KR20090033417A (ko) 2006-07-27 2009-04-03 씨브이 쎄러퓨틱스, 인코포레이티드 중독의 치료에서의 ａｌｄｈ-2 저해제
CL2007002218A1 (es) * 2006-08-03 2008-03-14 Celgene Corp Soc Organizada Ba Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
EP2069021A2 (en) * 2006-08-04 2009-06-17 AGI Therapeutics Research Limited Methods for treating at least one condition having mt1 receptor, 5ht2b receptor, and l-type calcium channel activity
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
CL2007002513A1 (es) 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
US20080213165A1 (en) * 2006-09-01 2008-09-04 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patent Tolerability During Myocardial Imaging Methods
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
JP2010503709A (ja) 2006-09-15 2010-02-04 レビバ ファーマシューティカルズ，インコーポレーテッド シクロアルキルメチルアミンの合成、使用方法および組成物
US7585996B2 (en) * 2006-09-15 2009-09-08 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
DK2066662T3 (da) 2006-09-21 2013-01-07 Kyorin Seiyaku Kk Serinhydrolaseinhibitorer
PL2428513T3 (pl) 2006-09-26 2017-10-31 Celgene Corp Pochodne 5-podstawionego chinazolinonu jako środki przeciwnowotworowe
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
WO2008042796A2 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
US7445528B1 (en) 2006-09-29 2008-11-04 Boston Scientific Neuromodulation Corporation Connector assemblies
BRPI0717502A2 (pt) * 2006-10-05 2015-06-16 Cv Therapeutics Inc Compostos heterocíclicos contendo nitrogênio bacíclico para uso como inibidores de estearoil-coa desaturase.
US7893066B2 (en) * 2006-10-05 2011-02-22 Gilead Palo Alto, Inc. Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2010522690A (ja) * 2006-10-12 2010-07-08 ゼノン・ファーマシューティカルズ・インコーポレイテッド 三環式スピロオキシインドール誘導体および治療薬としてのその使用
WO2008046049A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
ES2402907T3 (es) 2006-10-19 2013-05-10 Genzyme Corporation Roscovitina para el tratamiento de ciertas enfermedades quísticas
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US7347746B1 (en) 2006-10-27 2008-03-25 Boston Scientific Neuromodulation Corporation Receptacle connector assembly
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
AU2007322116B2 (en) 2006-11-13 2013-01-10 Synta Pharmaceuticals Corp. Cyclohexenyl-aryl compounds for inflammation and immune-related uses
MX2009005478A (es) 2006-11-27 2009-08-12 Lundbeck & Co As H Derivados de heteroarilamida.
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008066131A1 (fr) 2006-12-01 2008-06-05 Banyu Pharmaceutical Co., Ltd. Nouveau dérivé de phényl-isoxazol-3-ol
US7776868B2 (en) 2006-12-01 2010-08-17 Gilead Palo Alto, Inc. Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists
US9427570B2 (en) * 2006-12-06 2016-08-30 St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) Expandable stimulation leads and methods of use
WO2008070809A2 (en) 2006-12-06 2008-06-12 Spinal Modulation, Inc. Implantable flexible circuit leads and methods of use
AU2007329253B2 (en) 2006-12-06 2014-03-27 Spinal Modulation, Inc. Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels
WO2008070806A2 (en) * 2006-12-06 2008-06-12 Spinal Modulation, Inc. Hard tissue anchors and delivery devices
MX2009006080A (es) * 2006-12-08 2009-07-14 Xenoport Inc Uso de profarmacos de analogos de gaba para el tratamiento de enfermedades.
CN101626688A (zh) * 2006-12-11 2010-01-13 雷维瓦药品公司 茚满酮基胆碱酯酶抑制剂的组合物、合成和使用方法
SI2101777T1 (sl) 2006-12-12 2015-08-31 Gilead Sciences, Inc. Sestavek za zdravljenje pljučne hipertenzije
US20080147186A1 (en) * 2006-12-14 2008-06-19 Joshi Ashok V Electrochemical Implant For Delivering Beneficial Agents
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US7709527B2 (en) * 2006-12-21 2010-05-04 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
WO2008079387A1 (en) * 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CN101611008A (zh) * 2006-12-22 2009-12-23 恩希赛弗制药公司 C3a受体调节剂及其使用方法
AU2007343726A1 (en) * 2006-12-26 2008-07-24 Amgen Inc. N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CA2674039A1 (en) * 2006-12-28 2008-07-17 Astellas Pharma Inc. Sustained release formulation for tacrolimus
US20080267861A1 (en) * 2007-01-03 2008-10-30 Cv Therapeutics, Inc. Myocardial Perfusion Imaging
WO2008089260A2 (en) * 2007-01-16 2008-07-24 Victory Pharma, Inc. Combined administration of benzonatate and guaifenesin
NZ578078A (en) 2007-01-16 2011-11-25 Purdue Pharma Lp Heterocyclic-substituted piperidine as orl-1 ligands
US9044592B2 (en) * 2007-01-29 2015-06-02 Spinal Modulation, Inc. Sutureless lead retention features
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
KR20150008922A (ko) 2007-02-09 2015-01-23 메타베이시스 테라퓨틱스, 인크. 글루카곤 수용체의 길항제
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
SG175611A1 (en) 2007-02-21 2011-11-28 Sepracor Inc Solid forms comprising (-) o-desmethylvenlafaxine and uses thereof
BRPI0808089A2 (pt) 2007-02-28 2014-07-15 Conatus Pharmaceuticals Inc Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
CL2008000666A1 (es) * 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc Compuestos derivados de triciclos sustituidos, inhibidores del transportador de metales divalentes-1; y uso para tratar una enfermedad asociada con un trastorno del hierro.
WO2008112495A1 (en) * 2007-03-09 2008-09-18 Wyeth Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile
JP2010521444A (ja) * 2007-03-12 2010-06-24 バイオリポックス エービー 炎症の治療において有用なピペリジノン類
TW200846305A (en) 2007-03-15 2008-12-01 Auspex Pharmaceuticals Inc Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
US20080064701A1 (en) * 2007-04-24 2008-03-13 Ramesh Sesha Anti-diabetic combinations
CA2683409A1 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
CA2681560A1 (en) * 2007-04-09 2008-10-16 Cv Therapeutics, Inc. Pteridinone derivatives for use as stearoyl coa desaturase inhibitors
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US20080255161A1 (en) * 2007-04-11 2008-10-16 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
ES2963291T3 (es) 2007-04-26 2024-03-26 Sublimity Therapeutics Ltd Fabricación de múltiples minicápsulas
US20090176796A1 (en) 2007-04-27 2009-07-09 Purdue Pharma L. P. Trpv1 antagonists including amide substituent and uses thereof
KR20090130422A (ko) * 2007-04-27 2009-12-23 퍼듀 퍼머 엘피 통증 치료에 유용한 치료제
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
JP5466147B2 (ja) * 2007-05-21 2014-04-09 レビバ ファーマシューティカルズ，インコーポレーテッド キノリノン系非定型抗精神病薬剤の組成物、合成、及び使用方法
EP2019101A1 (en) * 2007-07-26 2009-01-28 GPC Biotech AG Pyrazol[3,4-d]pyrimidin-4-one useful as Kinase Inhibitor
CA2688493C (en) 2007-05-31 2016-04-19 Sepracor Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
EP2166843A4 (en) 2007-06-01 2010-08-11 Univ Princeton TREATMENT OF VIRUS INFECTIONS BY MODULATION OF HOST CELL METABOLISMS
WO2009011988A2 (en) * 2007-06-05 2009-01-22 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth
US20100240713A1 (en) * 2007-06-05 2010-09-23 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
US20080306076A1 (en) * 2007-06-08 2008-12-11 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US8633186B2 (en) 2007-06-08 2014-01-21 Senomyx Inc. Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en) * 2007-06-08 2011-04-19 Senomyx, Inc. Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
JP4827986B2 (ja) 2007-06-08 2011-11-30 マンカインド コーポレ−ション ＩＲＥ−１αインヒビター
US9603848B2 (en) * 2007-06-08 2017-03-28 Senomyx, Inc. Modulation of chemosensory receptors and ligands associated therewith
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
CA2690719A1 (en) * 2007-07-06 2009-01-15 Nuon Therapeutics, Inc. Treatment of neuropathic pain
EA201000016A1 (ru) * 2007-07-12 2010-10-29 Трагара Фармасьютикалс, Инк. Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
US8183381B2 (en) 2007-07-19 2012-05-22 Metabolex Inc. N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders
TWI444186B (zh) 2007-08-01 2014-07-11 Synta Pharmaceuticals Corp 用於發炎與免疫相關用途之雜環－芳基化合物
EP2185514A4 (en) 2007-08-01 2011-05-18 Synta Pharmaceuticals Corp VINYL-ARYL DERIVATIVES FOR INFLAMMATORY AND IMMUNE DISORDERS
US7893045B2 (en) 2007-08-07 2011-02-22 Celgene Corporation Methods for treating lymphomas in certain patient populations and screening patients for said therapy
PT2194783T (pt) 2007-08-10 2017-08-14 Vm Discovery Inc Composições e métodos para moduladores da apoptose
MX2010001784A (es) 2007-08-13 2010-03-15 Metabasis Therapeutics Inc Activadores novedosos de la glucocinasa.
WO2009027852A2 (en) * 2007-08-28 2009-03-05 Agi Therapeutics, P.L.C. Methods and compositions for treating gastrointestinal conditions
JP5554709B2 (ja) 2007-08-31 2014-07-23 パーデュー、ファーマ、リミテッド、パートナーシップ 置換キノキサリンタイプピペリジン化合物とその使用
US20090082315A1 (en) * 2007-09-05 2009-03-26 Raif Tawakol Compositions and Methods for Controlling Cholesterol Levels
WO2009035634A2 (en) * 2007-09-11 2009-03-19 Activx Biosciences, Inc. Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
BRPI0816814B1 (pt) 2007-09-12 2021-08-31 Kyorin Pharmaceutical Co. Ltd Composto, composição farmacêutica e uso de um composto
CZ300468B6 (cs) * 2007-09-20 2009-05-27 Zentiva, A. S Léková forma obsahující tramadol s kontrolovaným uvolnováním po dobu 24 hodin a zpusob její prípravy
EP2200999B1 (en) 2007-09-26 2014-08-13 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
AR068540A1 (es) * 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
CN101827860A (zh) * 2007-10-16 2010-09-08 西福根有限公司 包含最佳化her1和her3多聚体的组合物及其使用方法
CA2702494A1 (en) 2007-10-19 2009-04-23 The Regents Of The University Of California Compositions and methods for ameliorating cns inflammation, psychosis, delirium, ptsd or ptss
EP2221301B1 (en) 2007-11-12 2014-06-04 Msd K.K. Heteroaryloxy quinazoline derivative
MX2010005680A (es) 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
CA2706931C (en) 2007-12-06 2015-05-12 Durect Corporation Oral pharmaceutical dosage forms
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090162417A1 (en) * 2007-12-21 2009-06-25 Cook Incorporated Drug eluting ocular conformer
EP2236507A1 (en) 2007-12-25 2010-10-06 Banyu Pharmaceutical Co., Ltd. N-pyrazole-2-pyridinecarboxamide derivative
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
JP2011511802A (ja) * 2008-02-07 2011-04-14 ギリアード・パロ・アルト・インコーポレイテッド Ａｂｃａ−１を上昇させる化合物およびかかる化合物の使用方法
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
WO2009105256A2 (en) * 2008-02-20 2009-08-27 Celgene Corporation Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
KR101601997B1 (ko) 2008-03-17 2016-03-17 암비트 바이오사이언시즈 코포레이션 Ｒａｆ 키나아제 조절제로서의 퀴나졸린 유도체 및 그의 사용방법
US9249147B2 (en) 2008-03-19 2016-02-02 Chembridge Corporation Tyrosine kinase inhibitors
US8822500B2 (en) 2008-03-19 2014-09-02 Chembridge Corporation Tyrosine kinase inhibitors
US8815906B2 (en) 2008-03-19 2014-08-26 Chembridge Corporation Tyrosine kinase inhibitors
EP2687213B1 (en) 2008-03-27 2019-01-23 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
ES2476252T3 (es) 2008-03-27 2014-07-14 Celgene Corporation Formas sólidas que comprenden (+)-2-[1-(3-etoxi-4-metoxifenil)-2-metilsulfoniletil]-4-acetilaminoisoindolina-1,3-diona, composiciones de las mismas y usos de las mismas
DK2280704T3 (en) * 2008-03-31 2015-06-29 Cymabay Therapeutics Inc Oxymethylenarylforbindelser and uses thereof
EP2271349B1 (en) 2008-04-01 2017-03-15 Antipodean Pharmaceuticals, Inc. Compositions and methods for skin care
US8088792B2 (en) * 2008-04-04 2012-01-03 Gilead Sciences, Inc. Triazolopyridinone derivatives for use as stearoyl CoA desaturase inhibitors
WO2009128917A2 (en) 2008-04-14 2009-10-22 Halozyme, Inc. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
WO2009139880A1 (en) * 2008-05-13 2009-11-19 Celgene Corporation Thioxoisoindoline compounds and compositions and methods of using the same
KR20110036540A (ko) * 2008-05-20 2011-04-07 쎄레니스 떼라퓨틱스 에스.에이. 병용 요법을 위한 니아신 및 ｎｓａｉｄ
EP2299814A4 (en) * 2008-05-27 2011-06-15 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR USE OF ANTIPSYCHOTICS ON PIPERAZINE BASIS
EP2298750A4 (en) 2008-06-02 2012-04-25 Msd Kk NOVEL ISOXAZOLE DERIVATIVE
US8894602B2 (en) 2010-09-17 2014-11-25 Johnson & Johnson Vision Care, Inc. Punctal plugs with directional release
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
ES2458358T3 (es) 2008-07-02 2014-05-05 Idenix Pharmaceuticals, Inc. Compuestos y composiciones farmacéuticas para el tratamiento de infecciones víricas
PE20140102A1 (es) 2008-07-21 2014-02-06 Purdue Pharma Lp Compuestos de piperidina puenteada tipo quinoxalina sustituida con actividad sobre el receptor orl-1
US8173637B2 (en) * 2008-07-24 2012-05-08 Handa Pharmaceuticals, Llc Stabilized atypical antipsychotic formulation
US8530494B2 (en) 2008-07-30 2013-09-10 Purdue Pharma Lp Buprenophine analogs
MX2011001155A (es) 2008-07-31 2011-07-29 Senomyx Inc Composiciones que comprenden mejoradores del dulzor, y métodos para prepararlas.
UA117296C2 (uk) 2008-07-31 2018-07-10 Сіномікс, Інк. Способи і проміжні сполуки для одержання підсилювачів солодкого смаку
EP2326618B1 (en) 2008-08-13 2014-10-15 Metabasis Therapeutics, Inc. Glucagon antagonists
EP2348863A4 (en) 2008-09-04 2012-03-07 Anacor Pharmaceuticals Inc BORN SMALL MOLECULES
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
AU2009296235A1 (en) * 2008-09-29 2010-04-01 Gilead Sciences, Inc. Combinations of a rate control agent and an A-2-alpha receptor antagonist for use in multidetector computed tomography methods
AU2009300317A1 (en) * 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
WO2010039801A2 (en) 2008-10-02 2010-04-08 The J. David Gladstone Institutes Methods of treating hepatitis c virus infection
CN102216257B (zh) 2008-10-08 2015-11-25 凯飞药业公司 Gaba偶联物及其使用方法
EP2346329B1 (en) 2008-10-09 2013-08-21 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
LT2356109T (lt) 2008-10-10 2017-03-27 Vm Discovery, Inc. Kompozicijos ir būdai, skirti alkoholio vartojimo sutrikimų, skausmo ir kitų ligų gydymui
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
HUE025938T2 (en) * 2008-10-17 2016-05-30 Xenon Pharmaceuticals Inc Spiro oxindole compounds and their use as therapeutic agents
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
JP2012506386A (ja) * 2008-10-21 2012-03-15 メタボレックス， インコーポレイテッド アリールｇｐｒ１２０受容体アゴニストおよびその使用
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
US8759362B2 (en) * 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8703962B2 (en) * 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8546388B2 (en) * 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
US9056197B2 (en) 2008-10-27 2015-06-16 Spinal Modulation, Inc. Selective stimulation systems and signal parameters for medical conditions
EP3354646A1 (en) 2008-10-29 2018-08-01 Celgene Corporation Isoindoline compounds for use in the treatment of cancer
US20100113514A1 (en) 2008-10-30 2010-05-06 Gilead Palo Alto, Inc. Fused heterocyclic compounds as ion channel modulators
PT2352494T (pt) 2008-10-30 2019-11-15 Gruenenthal Gmbh Novas e potentes formas de dosagem de tapentadol
US8389500B2 (en) 2008-10-30 2013-03-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
EP2352505B1 (en) 2008-11-04 2016-07-06 University Of Kentucky Research Foundation D-tagatose-based compositions and methods for preventing and treating atherosclerosis, metabolic syndrome, and symptoms thereof
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
JP5752601B2 (ja) 2008-12-08 2015-07-22 ブイエム ファーマ エルエルシー タンパク質受容体チロシンキナーゼ阻害薬の組成物
RS58728B1 (sr) 2008-12-09 2019-06-28 Halozyme Inc Produženi rastvorljivi ph20 polipeptidi i njihove upotrebe
ES2421171T3 (es) 2008-12-16 2013-08-29 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción triples y su uso en métodos
EP2376633A1 (en) 2008-12-17 2011-10-19 AVI BioPharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010075255A2 (en) 2008-12-22 2010-07-01 Sloan-Kettering Institute For Cancer Research Methods for treating or preventing cancer and neurodegenerative diseases
WO2010075280A2 (en) 2008-12-22 2010-07-01 Sloan-Kettering Institute For Cancer Research Coumarin-based compounds
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
CN102307892A (zh) 2008-12-31 2012-01-04 西尼克斯公司 环孢菌素a的衍生物
AU2010203714C1 (en) 2009-01-06 2013-12-12 Galenagen, Llc Compositions and methods for the treatment or the prevention of infections by e. coli
CN105664144B (zh) 2009-01-06 2020-08-11 加尔纳根有限责任公司 治疗或预防金黄色葡萄球菌感染以及根除或减少表面上金黄色葡萄球菌的组合物和方法
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
JP5674684B2 (ja) 2009-02-03 2015-02-25 マイクロビオン コーポレーション 上皮組織、急性および慢性創傷、細菌性バイオフィルムならびに他の適応症のための消毒剤としてのビスマス−チオール
ES2553612T3 (es) 2009-02-09 2015-12-10 Sunovion Pharmaceuticals Inc. Inhibidores de la recaptación triple de pirrolidina
EP2818164A1 (en) 2009-02-10 2014-12-31 Celgene Corporation Methods of using and compositions comprising PDE4-modulators for treatment, prevention and management of tuberculosis
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
JP2012517471A (ja) 2009-02-11 2012-08-02 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
EP2396312A1 (en) 2009-02-11 2011-12-21 Celgene Corporation Isotopologues of lenalidomide
EP2396070A4 (en) 2009-02-12 2012-09-19 Incept Llc ACTIVE COMPOSITION WITH HYDROGEL PLUGS
WO2010095767A1 (en) 2009-02-23 2010-08-26 Banyu Pharmaceutical Co.,Ltd. Pyrimidin-4(3h)-one derivatives
KR20110124780A (ko) 2009-02-24 2011-11-17 리터 파마슈티컬즈 인코오포레이티드 프리바이오틱 제제 및 사용 방법
JP5337259B2 (ja) * 2009-02-26 2013-11-06 レビバ ファーマシューティカルズ，インコーポレーテッド アリールピペラジン誘導体の組成物、合成および利用方法
EP2448406B1 (en) 2009-02-26 2016-04-20 Relmada Therapeutics, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use
RU2529019C2 (ru) 2009-02-27 2014-09-27 Эмбит Байосайенсиз Корпорейшн Модулирующие jak киназу хиназолиновые производные и способы их применения
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
WO2010102262A1 (en) 2009-03-06 2010-09-10 Halozyme, Inc. Temperature sensitive mutants of matrix metalloprotease 1 und uses thereof
KR20140141727A (ko) 2009-03-10 2014-12-10 유로-셀티큐 에스.에이. 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
WO2010104205A1 (en) * 2009-03-11 2010-09-16 Kyorin Pharmaceutical Co., Ltd. 7-cycloalkylaminoquinolones as gsk-3 inhibitors
CA2754909A1 (en) 2009-03-11 2010-09-16 Ambit Biosciences Corp. Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
CA2754688A1 (en) 2009-03-11 2010-09-16 Msd K.K. Novel isoindolin-1-one derivative
JP2012520884A (ja) 2009-03-18 2012-09-10 ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー フラビウイルス科ウイルス感染症を治療する方法および組成物
JP2012521801A (ja) 2009-03-24 2012-09-20 スパイナル・モデュレーション・インコーポレイテッド 錯感覚に対する閾値以下の刺激を伴う疼痛の管理
JP5766177B2 (ja) 2009-03-27 2015-08-19 ベトディーシー，インコーポレイテッド ピリミジニル及び１，３，５−トリアジニルベンゾイミダゾールスルホンアミド及びガンの療法におけるその使用
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
AU2010239311B2 (en) 2009-04-20 2014-05-22 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
ES2664984T3 (es) 2009-04-22 2018-04-24 SMA Therapeutics, Inc. Arilsulfonamidas 2,5-disustituidas antagonistas de CCR3
PE20120809A1 (es) 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc Antagonistas ccr3 arilsulfonamida 2,5-disustituidos
SG2014005110A (en) 2009-04-22 2014-03-28 Axikin Pharmaceuticals Inc Arylsulfonamide ccr3 antagonists
EP2427430B1 (en) 2009-05-04 2014-09-10 The Royal Institution for the Advancement of Learning/McGill University 5-oxo-ete receptor antagonist compounds
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
EP2429407B1 (en) 2009-05-15 2018-10-17 Spinal Modulation Inc. Systems and devices for neuromodulating spinal anatomy
SG176145A1 (en) 2009-05-18 2011-12-29 Sigmoid Pharma Ltd Composition comprising oil drops
JP5645816B2 (ja) 2009-05-25 2014-12-24 国立大学法人東京工業大学 中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
BRPI0925100A2 (pt) 2009-06-02 2016-07-19 Dow Global Technologies Llc forma de dosagem osmótica e processo para preparar uma forma de dosagem osmótica
CA2764808A1 (en) 2009-06-10 2010-12-16 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
JP5775071B2 (ja) 2009-06-16 2015-09-09 ファイザー・インク アピキサバンの製剤形
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
JP5905387B2 (ja) 2009-07-08 2016-04-20 ホープ メディカル エンタープライゼズ，インコーポレイテッド ディービーエー ホープ ファーマシュティカルズＨｏｐｅ Ｍｅｄｉｃａｌ Ｅｎｔｅｒｐｒｉｓｅｓ，Ｉｎｃ．Ｄｂａ Ｈｏｐｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ チオ硫酸ナトリウムを含有する薬学的組成物
EP2451274B1 (en) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmaceutical compositions
TWI491606B (zh) 2009-07-13 2015-07-11 Gilead Sciences Inc 調節細胞凋亡信號之激酶的抑制劑
US20110020272A1 (en) 2009-07-24 2011-01-27 Ulrich Schubert Combination therapy for treating hepatitis viral infection
ES2642586T3 (es) 2009-07-27 2017-11-16 Gilead Sciences, Inc. Compuestos heterocíclicos condensados como moduladores de canales iónicos
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
EP2459184A1 (en) 2009-07-31 2012-06-06 The Brigham and Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US9878036B2 (en) 2009-08-12 2018-01-30 Sigmoid Pharma Limited Immunomodulatory compositions comprising a polymer matrix and an oil phase
US20110039799A1 (en) 2009-08-14 2011-02-17 Gilead Palo Alto, Inc. A1 adenosine receptor agonist polymorphs
WO2011022473A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
US20110060040A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
EP2473038A4 (en) 2009-09-04 2013-10-23 United Paragon Associates Inc COMPOSITIONS FOR TREATING SUFFICIENT OR ILLNESSES PROVIDED BY NEUROKININ-2-RECEPTOR ACTIVITY
US20120172350A1 (en) 2009-09-11 2012-07-05 Sunovion Pharmaceuticals Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
WO2011041154A1 (en) 2009-10-01 2011-04-07 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
US20110136751A1 (en) 2009-10-06 2011-06-09 Green Molecular Use of Polyphenols in the Treatment of Cancer
US8282970B2 (en) * 2009-10-07 2012-10-09 Jiahgsu Dehe Bio-Tech Co., Ltd Theaflavin compositions, related processes and methods of use
US20110082198A1 (en) * 2009-10-07 2011-04-07 Jiangsu Dehe Bio-Tech Co., Ltd. Theaflavin compositions, production, and methods to control physiological disorders in mammals
EP2488531B1 (en) * 2009-10-14 2014-03-26 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
RS53716B1 (en) 2009-10-19 2015-04-30 Synta Pharmaceuticals Corp. COMBINED CANCER THERAPY WITH HSP90 INHIBITORS
US8470817B2 (en) * 2009-10-26 2013-06-25 Sunesis Pharmaceuticals, Inc. Compounds and methods for treatment of cancer
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
AU2010315892B2 (en) 2009-11-09 2014-09-18 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
KR101769637B1 (ko) 2009-11-09 2017-08-18 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
WO2011063076A1 (en) 2009-11-19 2011-05-26 Itherx Pharmaceuticals, Inc. Methods of treating hepatitis c virus with oxoacetamide compounds
WO2011063102A1 (en) 2009-11-19 2011-05-26 Celgene Corporation Apremilast for the treatment of sarcoidosis
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
NZ731621A (en) 2009-12-04 2019-01-25 Sunovion Pharmaceuticals Inc Multicyclic compounds and methods of use thereof
BR112012013325B8 (pt) 2009-12-04 2021-05-25 Sunovion Pharmaceuticals Inc composição farmacêutica e uso
CN102869367A (zh) 2009-12-09 2013-01-09 西尼克斯公司 新颖的环肽
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2784748A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
WO2011079091A1 (en) 2009-12-22 2011-06-30 Celgene Corporation (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
EP2515654A4 (en) * 2009-12-23 2013-04-24 Map Pharmaceuticals Inc NEW ERGOLINANALOGA
CN102834409A (zh) 2009-12-30 2012-12-19 西尼克斯公司 环孢菌素类似物
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
HRP20221208T1 (hr) 2010-01-04 2022-12-09 Mapi Pharma Limited Depot sustav koji sadrži glatiramer acetat
EP2521543B1 (en) 2010-01-05 2016-04-13 Celgene Corporation A combination of an immunomodulatory compound and an artemisinin derivative for treating cancer
WO2011089167A1 (en) 2010-01-19 2011-07-28 Virologik Gmbh Kombination of proteasome inhibitors and anti -hepatitis medication for treating retroviral diseases
WO2011091164A1 (en) * 2010-01-22 2011-07-28 Xenoport, Inc. Oral dosage forms having a high loading of a tranexamic acid prodrug
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
UA115523C2 (uk) 2010-02-05 2017-11-27 Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка" Тверді форми макроциклічних інгібіторів кінази
US8471041B2 (en) * 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
EP3202460B1 (en) 2010-02-11 2019-06-12 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
AU2011223873B2 (en) 2010-03-02 2015-06-25 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
PT2545052E (pt) 2010-03-11 2015-02-18 Gilead Connecticut Inc Inibidores da syk à base de imidazopiridinas
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
AR080505A1 (es) 2010-03-12 2012-04-11 Celgene Corp Metodos para el tratamiento de linfoma no hodkin usando lenalidomida, y bimarcadores genicos y proteicos como indicadores
TW201134820A (en) 2010-03-17 2011-10-16 Axikin Pharmaceuticals Inc Arylsulfonamide CCR3 antagonists
EP2554168B1 (en) 2010-03-29 2018-01-24 Astellas Pharma Inc. Controlled release pharmaceutical composition
EP3799870A1 (en) 2010-04-05 2021-04-07 Fosun Orinove Pharmatech, Inc. Ire-1a inhibitors
WO2011127019A2 (en) 2010-04-07 2011-10-13 Celgene Corporation Methods for treating respiratory viral infection
CA2794565C (en) 2010-04-08 2018-08-21 Emory University Substituted androst-4-ene diones
WO2011133521A2 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
EP2563372A4 (en) 2010-04-28 2013-10-02 Ritter Pharmaceuticals Inc PREBIOTIC FORMULATIONS AND METHODS OF USE
WO2011140360A1 (en) 2010-05-05 2011-11-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
US20110276056A1 (en) 2010-05-10 2011-11-10 Grigsby Eric J Methods, systems and devices for reducing migration
US20120064175A1 (en) 2010-05-20 2012-03-15 Synta Pharmaceuticals Corp. HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients
WO2011146803A1 (en) 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
US20130171105A1 (en) 2010-05-24 2013-07-04 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
EP2576520A1 (en) 2010-05-28 2013-04-10 GE Healthcare UK Limited Radiolabeled compounds and methods thereof
JP5844354B2 (ja) 2010-06-01 2016-01-13 ビオトヘルイク， インコーポレイテッド ヒドロキシピリドン誘導体、その医薬組成物、及び増殖性疾患治療のためのその治療的使用
AU2011261501B2 (en) 2010-06-01 2016-01-21 Biotheryx, Inc. Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
CA2801778C (en) 2010-06-07 2018-06-05 Novomedix, Llc Furanyl compounds and the use thereof
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
DK2582674T3 (en) 2010-06-16 2014-12-15 Cymabay Therapeutics Inc GPR120 receptor agonists and uses thereof.
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CN109674753A (zh) 2010-06-23 2019-04-26 希玛贝治疗股份有限公司 固态分散体
US20120003329A1 (en) 2010-06-30 2012-01-05 Gilead Sciences, Inc. Use of A2B Adenosine Receptor Antagonists for Treating Pulmonary Hypertension
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
CN102985418B (zh) 2010-07-02 2015-09-09 吉利德科学股份有限公司 凋亡信号调节激酶抑制剂
EA026385B9 (ru) 2010-07-02 2017-08-31 Джилид Сайэнс, Инк. Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов
AU2011276170B2 (en) 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
WO2012007159A2 (en) 2010-07-14 2012-01-19 Grünenthal GmbH Novel gastro-retentive dosage forms
US20140200270A1 (en) 2013-01-11 2014-07-17 Summa Health System Vitamins c and k for treating polycystic diseases
WO2012012370A1 (en) 2010-07-19 2012-01-26 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
WO2012019093A1 (en) 2010-08-05 2012-02-09 Human Biomolecular Research Institute Synthetic compounds and methods to decrease nicotine self-administration
BR112013003332B1 (pt) 2010-08-12 2018-11-13 Senomyx, Inc. método para melhorar a estabilidade de intensificador de doce e composição contendo intensificador de doce estabilizado
CN103153295A (zh) 2010-08-24 2013-06-12 艾格埃克斯制药有限公司 来氟米特和丙二腈酰胺类似物的新用途
US9629644B2 (en) 2010-08-30 2017-04-25 SinuSys Corporation Devices and methods for dilating a paranasal sinus opening and for treating sinusitis
EP2611812A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
US20120053176A1 (en) 2010-09-01 2012-03-01 Ambit Biosciences Corp. Adenosine a3 receptor modulating compounds and methods of use thereof
KR20130141469A (ko) 2010-09-01 2013-12-26 암비트 바이오사이언시즈 코포레이션 피라졸릴아미노퀴나졸린의 브롬화수소 염
US20130296363A1 (en) 2010-09-01 2013-11-07 Ambit Biosciences Corporation Quinoline and isoquinoline derivatives for use as jak modulators
EP2611448A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030924A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Azolopyridine and azolopyrimidine compounds and methods of use thereof
WO2012030913A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
JP5901634B2 (ja) 2010-09-01 2016-04-13 アムビト ビオスシエンセス コルポラチオン キナゾリン化合物及びその使用方法
US20130225614A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 4-azolylaminoquinazoline derivatives and methods of use thereof
EP2611793A1 (en) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
US8821457B2 (en) 2010-09-08 2014-09-02 Johnson & Johnson Vision Care, Inc. Punctal plug containing drug formulation
US9000046B2 (en) 2010-09-28 2015-04-07 Depomed, Inc. Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
CN107050456B (zh) 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
MX2013003954A (es) 2010-10-11 2013-08-01 Axikin Pharmaceuticals Inc Sales de arilsulfonamida antagonistas de ccr3.
CN103458690B (zh) 2010-10-15 2016-03-16 吉利德科学股份有限公司 治疗肺动脉高压的组合物和方法
BR112013009196A2 (pt) 2010-10-15 2020-08-25 The Trustees Of Columbia University In The City Of New York usos de polipeptídeo para redução da aquisição de ácido graxo e da ingestão de alimento, bem como para promoção de saciedade relacionados à obesidade
NZ718514A (en) 2010-10-18 2017-10-27 Cerenis Therapeutics Holding Sa Compounds, compositions and methods useful for cholesterol mobilisation
CA2815024A1 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
CN103179962B (zh) 2010-10-29 2017-03-22 艾格埃克斯制药有限公司 丙二腈酰胺类似物在神经病理性疼痛中的用途
US20130289071A1 (en) 2010-11-09 2013-10-31 Synta Pharmaceuticals Corp. Tetrazolyl-tetrahydropyridine compounds for inflammation and immune-related uses
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
RU2013127625A (ru) 2010-11-18 2014-12-27 Зе Дженерал Хоспитал Корпорейшен Новые композиции и применения антигипертензивных средств для терапии рака
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
WO2012078492A1 (en) 2010-12-06 2012-06-14 Celgene Corporation A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
BR112013014021A8 (pt) 2010-12-06 2017-10-03 Follica Inc Métodos para tratamento de calvície e promoção de crescimento de cabelos
WO2012078757A2 (en) 2010-12-08 2012-06-14 Synta Pharmaceuticals Corp. Combination breast cancer therapy with hsp90 inhibitory compounds
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
CN103442698B (zh) 2010-12-16 2016-10-05 细胞基因公司 难溶性药物的控释口服剂量形式及其用途
US20120157938A1 (en) 2010-12-16 2012-06-21 Tokarski Jason M Punctal plug with drug core retention features
US9532977B2 (en) 2010-12-16 2017-01-03 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
EP2654751B1 (en) 2010-12-22 2016-11-23 Purdue Pharma L.P. Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
RS56344B1 (sr) 2010-12-22 2017-12-29 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
CN103327969A (zh) 2010-12-23 2013-09-25 普渡制药公司 抗篡改固体口服剂型
WO2013103919A2 (en) 2012-01-06 2013-07-11 Elcelyx Therapeutics, Inc. Compositions and methods for treating metabolic disorders
KR20140035331A (ko) 2011-01-07 2014-03-21 엘셀릭스 테라퓨틱스 인코포레이티드 화학감각 수용체 리간드-기반 요법
WO2012097000A1 (en) 2011-01-10 2012-07-19 Pingda Ren Processes for preparing isoquinolinones and solid forms of isoquinolinones
CN103391770A (zh) 2011-01-10 2013-11-13 细胞基因公司 环丙烷羧酸{2-[(1s)-1-(3-乙氧基-4-甲氧基-苯基)-2-甲烷磺酰基-乙基]-3-氧代-2,3-二氢-1h-异吲哚-4-基}-酰胺的口服剂型
CN103402980B (zh) 2011-01-10 2016-06-29 细胞基因公司 作为pde4和/或细胞因子抑制剂的苯乙基砜异吲哚啉衍生物
EP2663305A1 (en) 2011-01-11 2013-11-20 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
JP6106603B2 (ja) 2011-01-11 2017-04-05 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
EP2665477B1 (en) 2011-01-20 2015-09-09 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
EP2670426B1 (en) 2011-01-31 2017-05-10 The General Hospital Corporation Multimodal trail molecules and uses in cellular therapies
CA2825152A1 (en) 2011-01-31 2012-08-09 Celgene Corporation Pharmaceutical compositions of cytidine analogs and methods of use thereof
EP2670478B1 (en) 2011-02-02 2016-07-27 Spinal Modulation Inc. Devices and systemsfor the targeted treatment of movement disorders
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
WO2012116061A1 (en) 2011-02-23 2012-08-30 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with radiotherapy
AU2012243289A1 (en) 2011-02-24 2013-08-29 Synta Pharmaceuticals Corp. Prostate cancer therapy with Hsp90 inhibitory compounds
CN105001219A (zh) 2011-02-25 2015-10-28 默沙东公司 用作抗糖尿病药剂的新的环状氮杂苯并咪唑衍生物
US20140045908A1 (en) 2011-02-25 2014-02-13 Synta Pharmaceuticals Corp. Hsp90 inhibitory compounds in treating jak/stat signaling-mediated cancers
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
WO2012121988A2 (en) 2011-03-07 2012-09-13 Celgene Corporation Methods for treating diseases using isoindoline compounds
RU2013145556A (ru) 2011-03-11 2015-04-20 Селджин Корпорейшн Применение 3-(5-амино-2-метил-4-оксохиназолин-3(4н)-ил)пиперидин-2,6-диона в лечении иммунных и воспалительных заболеваний
CN103562197B (zh) 2011-03-11 2016-05-11 细胞基因公司 3-(5-氨基-2-甲基-4-氧-4h-喹唑啉-3-基)-哌啶-2,6-二酮的固体形式及其药物组合物和用途
EP2685983B1 (en) 2011-03-17 2016-05-18 Algiax Pharmaceuticals GmbH Novel use of imidazotriazinones
EP2685975A1 (en) 2011-03-17 2014-01-22 Algiax Pharmaceuticals GmbH Novel use of benzofuranylsulfonates
CA2830069C (en) 2011-03-20 2019-11-12 The University Of British Columbia Therapeutic agent for emphysema and copd
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
WO2012135299A1 (en) 2011-03-28 2012-10-04 Deuteria Pharmaceuticals Inc 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
WO2012135166A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2012135175A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
JP2014514295A (ja) 2011-03-31 2014-06-19 アイディニックス ファーマシューティカルズ インコーポレイテッド ウイルス感染の治療のための化合物および薬学的組成物
WO2012158271A1 (en) 2011-04-06 2012-11-22 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds as antiviral agents
AR085942A1 (es) 2011-04-07 2013-11-06 Gilead Sciences Inc Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio
EP2699317B1 (en) 2011-04-21 2016-08-10 Mapi Pharma Limited Random pentapolymer for treatment of autoimmune diseases
AU2012245287B2 (en) 2011-04-21 2017-04-13 Curemark, Llc Compounds for the treatment of neuropsychiatric disorders
JP6022548B2 (ja) 2011-04-28 2016-11-09 セルジーン コーポレイション Ｐｄｅ４阻害剤を自己免疫疾患及び炎症性疾患の治療及び管理に使用する方法及び組成物
KR20140024914A (ko) 2011-04-29 2014-03-03 셀진 코포레이션 예측인자로 세레브론을 사용하는 암 및 염증성 질환의 치료를 위한 방법
JP5985611B2 (ja) 2011-05-03 2016-09-06 シンタ ファーマシューティカルズ コーポレーション 炎症および免疫関連用途のための化合物
EP2704726B1 (en) 2011-05-04 2018-10-31 Trustees of Boston University Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
US9301874B2 (en) 2011-05-06 2016-04-05 Johnson & Johnson Vision Care, Inc. Punctal plugs for controlled release of therapeutic agents
EP3275870B1 (en) 2011-05-10 2020-02-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012162372A1 (en) 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
EP2718273A4 (en) 2011-06-07 2014-12-10 Anadys Pharmaceuticals Inc [1,2,4] -THIADIAZIN-1,1-DIOXIDE COMPOUNDS FOR REDUCING THE HUMAN ACID MIRROR IN THE SERUM
RU2011122942A (ru) 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
WO2012177678A2 (en) 2011-06-22 2012-12-27 Celgene Corporation Isotopologues of pomalidomide
KR20150055094A (ko) 2011-06-22 2015-05-20 퍼듀 퍼머 엘피 디히드록시 치환기를 포함하는 trpv1 길항제 및 그의 용도
WO2012175698A1 (en) 2011-06-23 2012-12-27 Université Libre de Bruxelles Therapeutic use of all-trans retinoic acid (atra) in patients suffering from alcoholic liver disease
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
TWI478908B (zh) 2011-07-01 2015-04-01 Gilead Sciences Inc 作為離子通道調節劑之稠合雜環化合物
NO3175985T3 (nl) 2011-07-01 2018-04-28
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
DE102011051653A1 (de) * 2011-07-07 2013-01-10 Lts Lohmann Therapie-Systeme Ag Quellfähige Manteltablette
WO2013006864A2 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
US10702485B2 (en) 2011-07-09 2020-07-07 Syntrix Biosystems Inc. Compositions and methods for overcoming resistance to tramadol
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201112987D0 (en) 2011-07-28 2011-09-14 Ge Healthcare Ltd Novel compound
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
EP2741760A2 (en) 2011-08-12 2014-06-18 B.S.R.C. "Alexander Fleming" Tnf superfamily trimerization inhibitors
EA201490472A1 (ru) 2011-08-19 2014-05-30 Синта Фармасьютиклз Корп. Комбинированная терапия рака hsp90-ингибитором и антиметаболитом
DK2959899T3 (en) 2011-08-23 2017-05-01 Cornerstone Therapeutics Inc Use of zileuton for the treatment of nasal polyps in patients with cystic fibrosis
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
TWI468403B (zh) 2011-08-30 2015-01-11 Gilead Sciences Inc 用於治療成癮之ａｌｄｈ－２抑制劑
WO2013033636A2 (en) 2011-09-01 2013-03-07 University Of Southern California Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
EP2755985B1 (en) 2011-09-12 2017-11-01 Idenix Pharmaceuticals LLC Compounds and pharmaceutical compositions for the treatment of viral infections
US20130071394A1 (en) 2011-09-16 2013-03-21 John K. Troyer Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
EP2758053A1 (en) 2011-09-21 2014-07-30 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
CA2849708A1 (en) 2011-09-23 2013-03-28 Celgene Corporation Romidepsin and 5 - azacitidine for use in treating lymphoma
EP2760456A1 (en) 2011-09-26 2014-08-06 Celgene Corporation Combination therapy for chemoresistant cancers
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
AU2012319071B2 (en) 2011-10-07 2017-08-03 Epicentrx, Inc. Organonitro thioether compounds and medical uses thereof
EP2764406B1 (en) 2011-10-07 2018-03-14 Cedars-Sinai Medical Center Compositions and methods for tumor imaging and targeting by a class of organic heptamethine cyanine dyes that possess dual nuclear and near-infrared properties
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
US20140271657A1 (en) 2011-10-12 2014-09-18 Children's Medical Center Corporation Combinatorial compositions and methods of treating hemoglobinopathies
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
PL2766359T3 (pl) 2011-10-14 2016-11-30 Związki heterocykliczne i ich zastosowanie jako modulatorów receptorowych kinaz tyrozynowych typu iii
CN104024251B (zh) 2011-10-31 2017-08-11 克赛农制药股份有限公司 苯磺酰胺化合物及其作为治疗剂的用途
SG11201401946QA (en) 2011-11-01 2014-05-29 Celgene Corp Methods for treating cancers using oral formulations of cytidine analogs
TWI615155B (zh) 2011-11-01 2018-02-21 拜耳股份有限公司 滲透活性的陰道遞送系統
JP2014534228A (ja) 2011-11-02 2014-12-18 シンタ ファーマシューティカルズ コーポレーション 白金含有剤とｈｓｐ９０阻害剤の組合せ療法
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013071049A1 (en) 2011-11-10 2013-05-16 Trustees Of Boston College Gramicidin a mutants that function as antibiotics with improved solubility and reduced toxicity
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
WO2013080036A1 (en) 2011-12-01 2013-06-06 Purdue Pharma L.P. Azetidine-substituted quinoxaline-type piperidine compounds and uses thereof
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013085902A1 (en) 2011-12-05 2013-06-13 The University Of Texas M.D. Combination therapy methods for treating an inflammatory breast cancer
SG11201402899TA (en) 2011-12-06 2014-07-30 Univ Leland Stanford Junior Methods and compositions for treating viral diseases
WO2013084060A1 (en) 2011-12-08 2013-06-13 Purdue Pharma L.P. Quaternized buprenorphine analogs
WO2013095707A1 (en) 2011-12-19 2013-06-27 Map Pharmaceuticals, Inc. Novel iso-ergoline derivatives
SG11201403433PA (en) 2011-12-21 2014-07-30 Map Pharmaceuticals Inc Novel neuromodulatory compounds
WO2013101926A1 (en) 2011-12-28 2013-07-04 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
WO2013101911A2 (en) 2011-12-28 2013-07-04 Allergan, Inc. Benzimidazole derivatives as selective blockers of persistent sodium current
EP3184525B1 (en) 2011-12-28 2020-10-28 Allergan, Inc. 3-phenyl-5-ureidoisothiazole-4-carboxamide derivatives as kinase inhibitors
BR112014016195A2 (pt) 2011-12-30 2020-10-27 Halozyme, Inc. variantes de polipeptídio ph20, formulações e usos das mesmas
JP2015507635A (ja) 2011-12-30 2015-03-12 レビバ ファーマシューティカルズ，インコーポレイティド 組成物、合成およびフェニルシクロアルキルメチルアミン誘導体を使用する方法
DK2800578T3 (en) 2012-01-05 2019-03-25 Boston Medical Ct Corp SLIT-ROBO SIGNAL FOR DIAGNOSIS AND TREATMENT OF Kidney Diseases
KR102035879B1 (ko) 2012-01-06 2019-10-23 엘셀릭스 테라퓨틱스 인코포레이티드 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
CA2862670A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
CA2864085C (en) 2012-02-08 2021-11-23 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
ES2671608T3 (es) 2012-02-21 2018-06-07 Celgene Corporation Formas sólidas de 3-(4-nitro-1-oxoisoindolin-2-il)piperidina-2,6-diona
WO2013130600A1 (en) 2012-02-29 2013-09-06 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
EP2819740A4 (en) 2012-02-29 2015-11-25 Sinusys Corp DEVICES AND METHOD FOR DILATING A PARANASAL SINUS OPENING AND FOR TREATING SINUSITIS
JP6403939B2 (ja) 2012-02-29 2018-10-10 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッドＪｏｈｎｓｏｎ ＆ Ｊｏｈｎｓｏｎ Ｖｉｓｉｏｎ Ｃａｒｅ， Ｉｎｃ． 電圧が印加される収容アレイを有する涙点プラグ
WO2013133708A1 (en) 2012-03-07 2013-09-12 Stichting Vu-Vumc Compositions and methods for diagnosing and treating intellectual disability syndrome, autism and autism related disorders
AU2013205240B2 (en) 2012-03-16 2016-02-11 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
CA2901394A1 (en) 2012-03-19 2013-09-26 The Brigham And Women's Hosptial, Inc. Growth differentiation factor (gdf) for treatment of diastolic heart failure
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US20140350087A9 (en) 2012-03-22 2014-11-27 Halozyme, Inc. Oncovector Nucleic Acid Molecules and Methods of Use
US9169207B2 (en) 2012-03-27 2015-10-27 Incuron, Llc Curaxins for use in treating carcinogen-induced cancer
CA2868258A1 (en) 2012-03-28 2013-10-03 Synta Pharmaceuticals Corp. Triazole derivatives as hsp90 inhibitors
WO2013152206A1 (en) 2012-04-04 2013-10-10 Synta Pharmaceuticals Corp. Novel triazole compounds that modulate hsp90 activity
JP6042527B2 (ja) 2012-04-04 2016-12-14 ハロザイム インコーポレイテッド 抗ヒアルロナン剤と腫瘍標的タキサンの組み合わせ治療
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013156232A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of benzofuranylsulfonates in neuropathic pain
WO2013156231A1 (en) 2012-04-16 2013-10-24 Algiax Pharmaceuticals Gmbh Use of imidazotriazinones in neuropathic pain
US8946253B2 (en) 2012-04-17 2015-02-03 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
EP3338776A1 (en) 2012-05-01 2018-06-27 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US20150099721A1 (en) 2012-05-10 2015-04-09 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
AR091027A1 (es) 2012-05-11 2014-12-30 Purdue Pharma Lp Analogos de benzomorfano y el usos de estos
US9074972B2 (en) 2012-05-16 2015-07-07 Dionex Corporation Surrogate addition device and a method of analyte concentration
MD20140134A2 (ro) 2012-05-22 2015-04-30 Idenix Pharmaceuticals, Inc. Compuşi ai D-aminoacizilor pentru tratamentul bolilor hepatice
EP2852605B1 (en) 2012-05-22 2018-01-31 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphate prodrugs for hcv infection
WO2013177188A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP3406598B1 (en) 2012-06-14 2020-01-29 Mayo Foundation for Medical Education and Research Pyrazole derivatives as inhibitors of stat3
WO2013188763A1 (en) 2012-06-15 2013-12-19 The Brigham And Women's Hospital, Inc. Compositions for treating cancer and methods for making the same
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US9857359B2 (en) 2012-06-29 2018-01-02 Celgene Corporation Methods for determining drug efficacy using cereblon-associated proteins
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
AU2013290100A1 (en) 2012-07-11 2015-01-29 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US20150259355A1 (en) 2012-07-16 2015-09-17 Rhodes Technologies Process for improved opioid synthesis
WO2014014427A1 (en) 2012-07-16 2014-01-23 Mahmut Bilgic Modified release pharmaceutical tablet formulations
AU2013291725B2 (en) 2012-07-16 2016-07-28 Rhodes Technologies Process for improved opioid synthesis
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
KR20150041040A (ko) 2012-08-06 2015-04-15 세노믹스, 인코포레이티드 단맛 향미 개질제
EP3524598B1 (en) 2012-08-09 2021-07-07 Celgene Corporation A solid form of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione hydrochloride
EP3741372A1 (en) 2012-08-09 2020-11-25 Celgene Corporation (s)-3-[4-(4-morphlin-4-ylmethylbenzyloxy)-1- oxo-1,3-dihydro-isoindo-2-yl]piperidine-2,6-dione for use in the treatment of immune-related and inflammatory diseases
TWI723266B (zh) 2012-08-09 2021-04-01 美商西建公司 利用3-(4-((4-(嗎啉基甲基)苄基)氧基)-1-氧異吲哚啉-2-基)六氫吡啶-2,6-二酮治療癌症之方法
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US10624859B2 (en) 2012-08-20 2020-04-21 Rhodes Technologies Systems and methods for increasing stability of dronabinol compositions
US9382243B2 (en) 2012-08-22 2016-07-05 Merck Sharp & Dohme Corp. Azabenzimidazole tetrahydropyran derivatives
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
EP2890720B1 (en) 2012-08-30 2019-07-17 The General Hospital Corporation Compositions and methods for treating cancer
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
JP2015527396A (ja) 2012-09-07 2015-09-17 アクシキン ファーマシューティカルズ インコーポレーテッド 同位体濃縮されたアリールスルホンアミドｃｃｒ３アンタゴニスト
CN104797256A (zh) 2012-09-10 2015-07-22 细胞基因公司 用于治疗局部晚期乳腺癌的方法
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
MX353422B (es) 2012-10-08 2018-01-12 Idenix Pharmaceuticals Llc Análogos de 2'-cloronucleósido para infección por vhc.
BR112015008118A2 (pt) 2012-10-12 2017-12-05 Brigham & Womens Hospital Inc reforço da resposta imune
US9278124B2 (en) 2012-10-16 2016-03-08 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP2909223B1 (en) 2012-10-19 2017-03-22 Idenix Pharmaceuticals LLC Dinucleotide compounds for hcv infection
EP2909222B1 (en) 2012-10-22 2021-05-26 Idenix Pharmaceuticals LLC 2',4'-bridged nucleosides for hcv infection
JP6584952B2 (ja) 2012-11-01 2019-10-02 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３キナーゼアイソフォームモジュレーターを用いる癌の治療
CA2890177A1 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
TW201431842A (zh) 2012-11-09 2014-08-16 Purdue Pharma Lp 苯並嗎啡烷類似物及其應用
WO2014074846A1 (en) 2012-11-09 2014-05-15 Celgene Corporation Methods for the treatment of bone loss
US20160151321A1 (en) 2012-11-13 2016-06-02 Dinesh C. Patel Methods for the treatment of sialorrhea
EP2920195A1 (en) 2012-11-14 2015-09-23 IDENIX Pharmaceuticals, Inc. D-alanine ester of rp-nucleoside analog
US20140140952A1 (en) 2012-11-14 2014-05-22 Idenix Pharmaceuticals, Inc. D-Alanine Ester of Sp-Nucleoside Analog
WO2014085284A1 (en) 2012-11-29 2014-06-05 Sunovion Pharmaceuticals Inc. Triazolo-pyrazine derivatives useful in the treatment of disorders of the central nervous system
CN107698470A (zh) 2012-11-30 2018-02-16 诺沃梅迪科斯有限公司 取代的二芳基磺酰胺及其用途
JP6317755B2 (ja) 2012-12-07 2018-04-25 パーデュー、ファーマ、リミテッド、パートナーシップ オピオイド受容体モジュレーターとしてのブプレノルフィン類似体
TW201427658A (zh) 2012-12-10 2014-07-16 Merck Sharp & Dohme 藉由投予升糖素受體拮抗劑及膽固醇吸收抑制劑治療糖尿病之方法
JP6141444B2 (ja) 2012-12-14 2017-06-07 パーデュー、ファーマ、リミテッド、パートナーシップ スピロ環式モルフィナンおよびこれらの使用
WO2014091295A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Pyridonemorphinan analogs and biological activity on opioid receptors
EP2931725B1 (en) 2012-12-14 2017-02-15 Purdue Pharma LP Nitrogen containing morphinan derivatives and the use thereof
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
ES2685568T3 (es) 2012-12-21 2018-10-10 Gilead Calistoga Llc Inhibidores de la isoquinolinona o quinazolinona fosfatidilinositol 3-quinasa
UY35212A (es) 2012-12-21 2014-06-30 Gilead Sciences Inc Inhibidores de la quinasa que regula la señal de la apoptosis
AU2013364068B2 (en) 2012-12-21 2016-10-20 Gilead Calistoga Llc Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
WO2014100354A1 (en) 2012-12-21 2014-06-26 Map Pharmaceuticals, Inc. Novel methysergide derivatives
WO2014102594A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102588A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
WO2014102589A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
WO2014102593A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. Substituted morphinans and the use thereof
WO2014102587A1 (en) 2012-12-28 2014-07-03 Purdue Pharma L.P. 7,8-cyclicmorphinan analogs
AU2013369649B2 (en) 2012-12-31 2018-07-26 Sunovion Pharmaceuticals Inc. Heterocyclic compounds and methods of use thereof
SG11201505240QA (en) 2013-01-05 2015-08-28 Elcelyx Therapeutics Inc Delayed-release composition comprising biguanide
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
WO2014110127A1 (en) 2013-01-08 2014-07-17 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
US9617607B2 (en) 2013-01-08 2017-04-11 Enzo Biochem, Inc. Diagnosis and treatment of viral diseases
US8999393B1 (en) 2013-01-09 2015-04-07 Edgemont Pharmaceuticals Llc Sustained release formulations of lorazepam
CA2897313A1 (en) 2013-01-09 2014-07-17 Edgemont Pharmaceuticals Llc Controlled release formulations of lorazepam
JP6359563B2 (ja) 2013-01-14 2018-07-18 デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
JP6406713B2 (ja) 2013-01-30 2018-10-17 ファーモレックス セラピューティクス， インコーポレイテッド 低用量薬剤によるうつ病および他の疾患の処置
EP2951160B1 (en) 2013-01-31 2019-04-24 Purdue Pharma LP Benzomorphan analogs and the use thereof
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
BR112015019546A2 (pt) 2013-02-15 2017-07-18 Allergan Inc implante de distribuição de drogas prolongado
JO3155B1 (ar) 2013-02-19 2017-09-20 Senomyx Inc معدِّل نكهة حلوة
WO2014130922A1 (en) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2014134419A1 (en) 2013-03-01 2014-09-04 Gilead Sciences, Inc. Use of ikach blockers for the treatment of cardiac diseases
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
AU2014235273A1 (en) 2013-03-14 2015-07-09 Celgene Corporation Treatment of psoriatic arthritis using apremilast
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
SG11201507101XA (en) 2013-03-15 2015-10-29 Univ California Acyclic nucleoside phosphonate diesters
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
AU2014228858A1 (en) 2013-03-15 2015-09-10 The Regents Of The University Of California Dual reactivity potent Kunitz inhibitor of fibrinolysis
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
WO2014151386A1 (en) 2013-03-15 2014-09-25 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
BR112015025252A2 (pt) 2013-04-02 2017-07-18 Celgene Corp métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
US10092627B2 (en) 2013-04-08 2018-10-09 President And Fellows Of Harvard College Methods and compositions for rejuvenating skeletal muscle stem cells
WO2014179453A1 (en) 2013-04-30 2014-11-06 Abbvie, Inc. Methods for improving lipid profiles using atrasentan
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
US9687263B2 (en) 2013-05-30 2017-06-27 SinuSys Corporation Devices and methods for inserting a sinus dilator
EP3003309B1 (en) 2013-05-30 2020-09-09 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2014197835A2 (en) 2013-06-06 2014-12-11 The General Hospital Corporation Methods and compositions for the treatment of cancer
EP3007719B1 (en) 2013-06-11 2021-03-17 President and Fellows of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
US10017531B2 (en) 2013-06-14 2018-07-10 Invictus Oncology Pvt. Ltd. Lipid-based platinum-N-heterocyclic carbene compounds and nanoparticles
US9221795B2 (en) 2013-06-14 2015-12-29 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
WO2014210596A1 (en) 2013-06-28 2014-12-31 Purdue Pharma L.P. Treating an arrhythmia with an opioid antagonist
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
EP3021946A2 (en) 2013-07-16 2016-05-25 Karakossian, Movses Hcn inhibitors affecting ganglion cell function and visual function
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
EP3027601B1 (en) 2013-07-31 2017-10-25 Gilead Sciences, Inc. Syk inhibitors
US20150037282A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CN110172063A (zh) 2013-08-02 2019-08-27 庄信万丰股份有限公司 用于制备氢羟吗啡酮的方法
WO2015027146A1 (en) 2013-08-22 2015-02-26 The General Hospital Corporation Inhibitors of human 12/15-lipoxygenase
US11382883B2 (en) 2013-08-29 2022-07-12 Trustees Of Boston University Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections
RU2016111675A (ru) 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
ES2729642T3 (es) 2013-09-24 2019-11-05 Purdue Pharma Lp Tratamiento del dolor por quemaduras mediante moduladores de TRPV1
WO2015051336A1 (en) 2013-10-03 2015-04-09 David Wise Compositions and methods for treating pelvic pain and other conditions
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
DK3052485T3 (da) 2013-10-04 2021-10-11 Infinity Pharmaceuticals Inc Heterocykliske forbindelser og anvendelser deraf
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3683321B1 (en) 2013-10-21 2021-12-08 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
WO2015061683A1 (en) 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015065876A1 (en) 2013-10-29 2015-05-07 Thomas Jefferson University Methods of prevention or treatment for pathologic thrombosis or inflammation
EP3063165A1 (en) 2013-11-01 2016-09-07 Idenix Pharmaceuticals LLC D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2931677A1 (en) 2013-11-26 2015-06-04 Gilead Sciences, Inc. Quinoline derivatives as bromodomain inhibitors
EP4053560A1 (en) 2013-11-26 2022-09-07 The Brigham and Women's Hospital, Inc. Compositions and methods for modulating an immune response
WO2015081133A2 (en) 2013-11-27 2015-06-04 Idenix Pharmaceuticals, Inc. Nucleotides for the treatment of liver cancer
US20170198005A1 (en) 2013-11-27 2017-07-13 Idenix Pharmaceuticals Llc 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
CN105764516A (zh) 2013-12-04 2016-07-13 吉利德科学公司 治疗癌症的方法
ES2912283T3 (es) 2013-12-11 2022-05-25 Massachusetts Gen Hospital Uso de proteínas de tipo sustancia inhibidora mülleriana (SIM) para la anticoncepción y conservación de la reserva ovárica
WO2015095419A1 (en) 2013-12-18 2015-06-25 Idenix Pharmaceuticals, Inc. 4'-or nucleosides for the treatment of hcv
KR101918375B1 (ko) 2013-12-19 2018-11-13 길리애드 사이언시즈, 인코포레이티드 이온 채널 조정제로서의 융합된 헤테로시클릭 화합물
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
CA2934344A1 (en) 2013-12-20 2015-06-25 David T. TING Methods and assays relating to circulating tumor cells
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
US9862726B2 (en) 2013-12-26 2018-01-09 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
EP3087073B1 (en) 2013-12-26 2018-07-04 Purdue Pharma LP 10-substituted morphinan hydantoins
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
US10550088B2 (en) 2013-12-27 2020-02-04 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
EP3089978B1 (en) 2013-12-30 2018-08-29 Purdue Pharma L.P. Pyridone-sulfone morphinan analogs as opioid receptor ligands
AU2015207733A1 (en) 2014-01-15 2016-07-14 Rhodes Technologies Process for improved oxycodone synthesis
WO2015109037A1 (en) 2014-01-15 2015-07-23 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
AU2015207734B2 (en) 2014-01-15 2017-02-23 Rhodes Technologies Process for improved oxymorphone synthesis
WO2015112568A1 (en) 2014-01-24 2015-07-30 Celgene Corporation Methods for the treatment of obesity using apremilast
US9346788B2 (en) 2014-02-05 2016-05-24 VM Oncology, LLC TrkA receptor tyrosine kinase antagonists and uses thereof
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015138420A1 (en) 2014-03-10 2015-09-17 Kadmon Corporation, Llc Treatment of brain and central nervous system tumors
PL3119744T3 (pl) 2014-03-18 2019-07-31 Algiax Pharmaceuticals Gmbh Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
CA2943220C (en) 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
CN106661027B (zh) 2014-03-20 2019-12-24 卡佩拉医疗公司 苯并咪唑衍生物作为erbb酪氨酸激酶抑制剂用于治疗癌症
US11369588B2 (en) 2014-03-20 2022-06-28 The Trustees Of Princeton University NADPH production by the 10-formyl-THF pathway, and its use in the diagnosis and treatment of disease
US20170107300A1 (en) 2014-03-21 2017-04-20 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US20150283149A1 (en) 2014-04-02 2015-10-08 Gilead Sciences, Inc. Methods of treating patients having implantable cardiac devices
BR112016022499A2 (pt) 2014-04-03 2017-08-15 Invictus Oncology Pvt Ltd Produtos terapêuticos combinatórios supramoleculares
WO2015153841A1 (en) 2014-04-04 2015-10-08 Ritter Pharmaceuticals, Inc. Methods and compositions for microbiome alteration
CA2944549A1 (en) 2014-04-09 2015-10-15 Siteone Therapeutics, Inc. 10',11'-modified saxitoxin useful for the treatment of pain
EP2933002A1 (en) 2014-04-11 2015-10-21 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of dabigatran and proton pump inhibitors
WO2015155307A1 (en) 2014-04-11 2015-10-15 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
EP3131914B1 (en) 2014-04-16 2023-05-10 Idenix Pharmaceuticals LLC 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
CA2983794A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
AU2015249716A1 (en) 2014-04-25 2016-11-03 Johnson & Johnson Vision Care, Inc. Method and ophthalmic device with active agent release system
CA2983796A1 (en) 2014-04-25 2015-10-29 The Brigham And Women's Hospital, Inc. Compositions and methods for treating subjects with immune-mediated diseases
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP3444011A1 (en) 2014-05-12 2019-02-20 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with emricasan
WO2015175773A1 (en) 2014-05-15 2015-11-19 Celgene Corporation Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
EP3142663A1 (en) 2014-05-16 2017-03-22 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
JP6817073B2 (ja) 2014-05-19 2021-01-20 ノースイースタン ユニバーシティ セロトニン受容体を標的にする化合物および方法
EP3145500A1 (en) 2014-05-23 2017-03-29 Sigmoid Pharma Limited Celecoxib formulations useful for treating colorectal cancer
CA2947939A1 (en) 2014-05-28 2015-12-03 Idenix Pharmaceuticals Llc Nucleoside derivatives for the treatment of cancer
AU2015270925A1 (en) 2014-06-02 2016-12-22 Children's Medical Center Corporation Methods and compositions for immunomodulation
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
WO2015191900A1 (en) 2014-06-12 2015-12-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
CN106459005A (zh) 2014-06-13 2017-02-22 吉利德科学公司 磷脂酰肌醇3‑激酶抑制剂
SG11201610088XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
US9527815B2 (en) 2014-06-18 2016-12-27 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
HUE042390T2 (hu) 2014-06-19 2019-06-28 Ariad Pharma Inc Heteroaril vegyületek kinázgátlásra
US10300042B2 (en) 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
EP3827836A1 (en) 2014-06-27 2021-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EP3169366A1 (en) 2014-07-14 2017-05-24 Gilead Sciences, Inc. Combinations for treating cancers
CA2910865C (en) 2014-07-15 2016-11-29 Isa Odidi Compositions and methods for reducing overdose
CN114470207B (zh) 2014-08-01 2023-09-19 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
EP3188745A1 (en) 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
CN107073115A (zh) 2014-08-22 2017-08-18 细胞基因公司 用免疫调节化合物与抗体组合治疗多发性骨髓瘤的方法
TR201907471T4 (tr) 2014-08-28 2019-06-21 Halozyme Inc Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
KR20170070022A (ko) 2014-08-29 2017-06-21 칠드런'즈 메디컬 센터 코포레이션 암의 치료를 위한 방법 및 조성물
SG10201902137PA (en) 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
SG10201901242PA (en) 2014-09-14 2019-03-28 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
HUE059067T2 (hu) 2014-09-15 2022-10-28 Univ California Nukleotid analógok
JP7095990B2 (ja) 2014-09-18 2022-07-05 シーダーズ－サイナイ メディカル センター 線維症を治療するための組成物及び方法
US10040781B2 (en) 2014-09-26 2018-08-07 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
US9403803B2 (en) 2014-10-08 2016-08-02 Allergan, Inc. Indole-3-carboxamides as kinase inhibitors
US9359336B2 (en) 2014-10-09 2016-06-07 Allergan, Inc. Heterocycle-substituted pyridyl benzothiophenes as kinase inhibitors
US9296747B1 (en) 2014-10-10 2016-03-29 Allergan, Inc. Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2
ES2753391T3 (es) 2014-10-14 2020-04-08 Halozyme Inc Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
EP3206708B1 (en) 2014-10-16 2022-11-02 Cleveland Biolabs, Inc. Methods and compositions for the treatment of radiation-related disorders
PT3209647T (pt) 2014-10-21 2020-09-10 Ariad Pharma Inc Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidino-2,4-diamina
EP3209658A1 (en) 2014-10-24 2017-08-30 Biogen MA Inc. Diterpenoid derivatives and methods of use thereof
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
EP3881829A1 (en) 2014-11-07 2021-09-22 Sublimity Therapeutics Limited Compositions comprising cyclosporin
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EA201791346A1 (ru) 2014-12-16 2018-01-31 Селджин Корпорейшн ТВЕРДЫЕ ФОРМЫ, ВКЛЮЧАЮЩИЕ (1E,4E)-2-АМИНО-N,N-ДИПРОПИЛ-8-(4-(ПИРРОЛИДИН-1-КАРБОНИЛ)ФЕНИЛ)-3H-БЕНЗО[b]-АЗЕПИН-4-КАРБОКСАМИД, ИХ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
US9676793B2 (en) 2014-12-23 2017-06-13 Hoffmann-Laroche Inc. Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
NZ733950A (en) 2014-12-23 2018-08-31 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
WO2016115039A1 (en) 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating pulmonary hypertension
CN107249592A (zh) 2015-01-12 2017-10-13 雷维瓦药品公司 用于治疗阿尔茨海默病的方法
JP7152156B2 (ja) 2015-01-14 2022-10-12 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 抗ｌａｐモノクローナル抗体による癌の処置
AU2016209492B2 (en) 2015-01-20 2020-10-22 Xoc Pharmaceuticals, Inc Ergoline compounds and uses thereof
JP2018502889A (ja) 2015-01-20 2018-02-01 エックスオーシー ファーマシューティカルズ インコーポレイテッドＸｏｃ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ イソエルゴリン化合物およびその使用
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9682033B2 (en) 2015-02-05 2017-06-20 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2016130502A1 (en) 2015-02-09 2016-08-18 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer
WO2016132217A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Method of improving gaba-b receptor agonist therapy
WO2016142877A1 (en) 2015-03-10 2016-09-15 Rhodes Technologies Acetate salt of buprenorphine and methods for preparing buprenorphine
TW201642857A (zh) 2015-04-06 2016-12-16 西建公司 以組合療法治療肝細胞癌
CN114366802A (zh) 2015-04-22 2022-04-19 西达-赛奈医疗中心 用于治疗2型糖尿病的肠内递送的苦味寡肽
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
WO2016189055A1 (en) 2015-05-27 2016-12-01 Idenix Pharmaceuticals Llc Nucleotides for the treatment of cancer
EP3303286B1 (en) 2015-06-01 2023-10-04 Cedars-Sinai Medical Center Compounds that bind to rela of nf-kb for use in treating cancer
WO2016202721A1 (en) 2015-06-16 2016-12-22 F. Hoffmann-La Roche Ag Salts of (s)-4-[(r)-6-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-3,6- dihydro-pyrimidin-4-ylmethyl]-morpholine-3-carboxylic acid, salt former and methods for preparing and using the same
EP3313402B1 (en) 2015-06-23 2023-12-27 Neurocrine Biosciences, Inc. Vmat2 inhibitors for treating neurological diseases or disorders
SI3313818T1 (sl) 2015-06-26 2024-03-29 Celgene Corporation Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
MX2018000216A (es) 2015-07-02 2018-05-22 Celgene Corp Terapia de combinacion para el tratamiento de canceres hematologicos y tumores solidos.
ES2872076T3 (es) 2015-07-06 2021-11-02 Gilead Sciences Inc Derivado de 4,6-diamino-quinolina-3-carbonitrilo en forma de modulador de cáncer Osaka tiroides (Cot) para el tratamiento de la enfermedad inflamatoria
RU2018107227A (ru) 2015-07-28 2019-08-28 Виоме Терапьютикс Лимитед Терапевтические и профилактические антибактериальные средства
US10940204B2 (en) 2015-07-31 2021-03-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
RS59158B9 (sr) 2015-08-17 2020-09-30 Kura Oncology Inc Postupci lečenja pacijenata obolelih od kancera pomoću inhibitora farneziltransferaze
EP3341392A4 (en) 2015-08-27 2019-01-23 President and Fellows of Harvard College COMPOSITIONS AND METHODS FOR TREATING PAIN
EP3347486A4 (en) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York REDUCTION OF ER-MAM-LOCALIZED APP-C99 AND METHOD FOR THE TREATMENT OF ALZHEIMER DISEASE
TWI679012B (zh) 2015-09-11 2019-12-11 法德生技藥品股份有限公司 含有達方吡啶的緩釋口服滲透錠劑及其用途
ES2930848T3 (es) 2015-09-23 2022-12-22 Xwpharma Ltd Profármacos de ácido gamma-hidroxibutírico, composiciones y usos de los mismos
US10702586B2 (en) 2015-09-28 2020-07-07 Children's Hospital Los Angeles Methods for treating diseases mediated by ErbB4-positive pro-inflammatory macrophages
WO2017059385A1 (en) 2015-09-30 2017-04-06 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
AU2016331076B2 (en) 2015-10-01 2020-12-03 Nighthawk Biosciences, Inc. Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
WO2017059459A1 (en) 2015-10-01 2017-04-06 Elysium Therapeutics, Inc. Polysubunit opioid prodrugs resistant to overdose and abuse
US20190255107A1 (en) 2015-10-09 2019-08-22 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
WO2017064657A1 (en) 2015-10-16 2017-04-20 Invictus Oncology Pvt. Ltd. Fluorescent anticancer platinum drugs
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
SI3875459T1 (sl) 2015-10-30 2024-06-28 Neurocrine Biosciences, Inc., Valbenazin dihidrokloridne soli in njihovi polimorfi
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3373916A1 (en) 2015-11-11 2018-09-19 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CU20180059A7 (es) 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
RS63170B1 (sr) 2015-12-23 2022-05-31 Neurocrine Biosciences Inc Sintetički postupak za pripremanje (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1,-a]izohinolin-2-il 2-amino-3-metilbutanoat di(4-metilbenzensulfonata)
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
WO2017117478A1 (en) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
CA3010794A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses
WO2017120446A1 (en) 2016-01-08 2017-07-13 Celgene Corporation Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies
ES2832475T3 (es) 2016-01-08 2021-06-10 Celgene Corp Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
PL3402480T4 (pl) 2016-01-11 2021-11-22 Epicentrx, Inc. Kompozycje i sposoby dożylnego podawania 2-bromo-1-(3,3-dinitroazetydyn-1-ylo)etanonu
EP3998281A1 (en) 2016-02-05 2022-05-18 Orionis Biosciences BV Cd8 binding agents
ES2858753T3 (es) 2016-02-19 2021-09-30 Phoenix Molecular Designs Derivados de 6-oxo-N-(1-(bencil)-1H-pirazol-4-il)-6,7,8,9-tetrahidropirido[3',2':4,5]pirrolo[1,2-a]pirazin-2-carboxamida como inhibidores de cinasa S6 ribosómica (RSK) p90 para el tratamiento del cáncer
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
CA3016081A1 (en) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions and combinations of autotaxin inhibitors
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2017153402A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
CN109476635B (zh) 2016-04-29 2021-07-13 Fgh生物科技公司 用于治疗疾病的二取代吡唑类化合物
WO2017192858A1 (en) 2016-05-04 2017-11-09 Purdue Pharma L.P. Oxazoline pseudodimers, pharmaceutical compositions and the use thereof
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
EP3454887B1 (en) 2016-05-13 2021-01-20 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
SG10201912216VA (en) 2016-05-20 2020-02-27 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
AU2017289158C1 (en) 2016-06-30 2020-07-23 Gilead Sciences, Inc. 4,6-diaminoquinazolines as Cot modulators and methods of use thereof
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN109562108A (zh) 2016-07-18 2019-04-02 法米娜生物技术公司 用于治疗与c反应蛋白相关的疾病的1-甲基烟酰胺
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
MA45857A (fr) 2016-07-29 2021-05-19 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
JP2019523279A (ja) 2016-07-29 2019-08-22 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 化合物および組成物ならびにそれらの使用
CA3032432A1 (en) 2016-08-03 2018-02-08 Charles A. Mcwherter Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
US11339142B2 (en) 2016-09-07 2022-05-24 Fgh Biotech, Inc. Di-substituted pyrazole compounds for the treatment of diseases
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US10111882B2 (en) 2016-09-14 2018-10-30 Gilead Sciences, Inc. SYK inhibitors
TW201822764A (zh) 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
WO2018057808A1 (en) 2016-09-23 2018-03-29 Gilead Sciences, Inc. Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
US20200016202A1 (en) 2016-10-07 2020-01-16 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
WO2018069312A1 (en) 2016-10-11 2018-04-19 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
MX2019004280A (es) 2016-10-14 2019-09-18 Epicentrx Inc Organonitro-sulfoalquilo y compuestos relacionados y composiciones farmacéuticas para uso en medicina.
EP3528805B1 (en) 2016-10-21 2023-12-06 Cedars-Sinai Medical Center Simvastatin and chemotherapeutic conjugates comprising a heptamethine carbocyanine dye for resensitising human tumors to hormonal antagonists and chemotherapy
US11084859B2 (en) 2016-10-24 2021-08-10 Orionis Biosciences BV Targeted mutant interferon-gamma and uses thereof
TW201818965A (zh) 2016-11-03 2018-06-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CN116987014A (zh) 2016-11-09 2023-11-03 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
CA3045121A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
EP4400171A2 (en) 2016-12-02 2024-07-17 Neurocrine Biosciences, Inc. Use of valbenazine for treating schizophrenia or schizoaffective disorder
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
JP7022751B2 (ja) 2016-12-09 2022-02-18 ゼノン・ファーマシューティカルズ・インコーポレイテッド ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用
US10784877B2 (en) 2016-12-21 2020-09-22 Johnson & Johnson Vision Care, Inc. Extended period timer circuits for ophthalmic devices
WO2018115888A1 (en) 2016-12-21 2018-06-28 N4 Pharma Uk Limited Novel formulations of aprepitant
AU2018206552A1 (en) 2017-01-04 2019-07-18 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
US20190338018A1 (en) 2017-01-04 2019-11-07 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
EP3573979A1 (en) 2017-01-27 2019-12-04 Celgene Corporation 3-(1-oxo-4-((4-((3-oxomorpholino) methyl)benzyl)oxy)isoindolin-2-yl)piperidine-2,6-dione and isotopologues thereof
US20190381016A1 (en) 2017-01-27 2019-12-19 Neurocrine Biosciences, Inc. Methods for the Administration of Certain VMAT2 Inhibitors
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
CN110546160A (zh) 2017-02-06 2019-12-06 奥里尼斯生物科学公司 靶向嵌合蛋白及其用途
JOP20180009A1 (ar) 2017-02-06 2019-01-30 Gilead Sciences Inc مركبات مثبط فيروس hiv
US10889587B2 (en) 2017-02-06 2021-01-12 Spero Therapeutics, Inc. Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
WO2018148745A1 (en) 2017-02-13 2018-08-16 Praxis Precision Medicines , Inc. Compounds and their methods of use
CA3053903A1 (en) 2017-02-16 2018-08-23 Sunovion Pharmaceuticals Inc. Methods of treating schizophrenia
US9956215B1 (en) 2017-02-21 2018-05-01 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR102138904B1 (ko) 2017-02-21 2020-07-28 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
WO2018157163A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Vsig8-based chimeric proteins
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
WO2018165142A1 (en) 2017-03-07 2018-09-13 Celgene Corporation Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
EP3595663A4 (en) 2017-03-17 2021-01-13 Elysium Therapeutics, Inc. MULTI-UNIT OPIOID MEDICINES RESISTANT TO OVERDOSE AND ABUSE
US11555031B2 (en) 2017-03-20 2023-01-17 The Broad Institute, Inc. Compounds and methods for regulating insulin secretion
CA3050086A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
BR112019017962A2 (pt) 2017-03-27 2020-05-19 Univ California método para inibição de crescimento, de migração, de proliferação e/ou de metástase de uma célula pré-cancerosa, cancerosa ou neoplásica ou de inibição de um patógeno, composição probiótica tópica, bandagem ou curativo, método de tratamento de dano na pele devido à radiação uv, e, composição farmacêutica
CN110914276A (zh) 2017-03-29 2020-03-24 赛特温治疗公司 用于治疗疼痛的11,13-修饰的石房蛤毒素类化合物
KR20200012833A (ko) 2017-03-29 2020-02-05 사이트원 테라퓨틱스, 인코포레이티드 통증 치료용 11,13-개질된 색시톡신
US11731966B2 (en) 2017-04-04 2023-08-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
WO2018200605A1 (en) 2017-04-26 2018-11-01 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
EP3624796A1 (en) 2017-05-19 2020-03-25 NFlection Therapeutics, Inc. Pyrrolopyridine-aniline compounds for treatment of dermal disorders
ES2913213T3 (es) 2017-05-19 2022-06-01 Nflection Therapeutics Inc Compuestos heteroaromáticos de anilina condensados para el tratamiento de trastornos dérmicos
EP3630079A4 (en) 2017-05-31 2021-02-24 The Children's Medical Center Corporation TARGETING LYSINE DEMETHYLASE (KDMS) AS A THERAPEUTIC STRATEGY FOR DIFFUSED LARGE B-CELL LYMPHOMA
BR112019025420A2 (pt) 2017-06-01 2020-06-16 Xoc Pharmaceuticals, Inc. Compostos policíclicos e usos destes
US11400136B2 (en) 2017-06-19 2022-08-02 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
WO2019005874A1 (en) 2017-06-26 2019-01-03 The Trustees Of Columbia University In The City Of New York CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER
BR112020000196A2 (pt) 2017-07-07 2020-07-07 Epicentrx, Inc. composições para administração parenteral de agentes terapêuticos
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CA3070993A1 (en) 2017-08-02 2019-02-07 Sunovion Pharmaceuticals Inc. Isochroman compounds and uses thereof
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3664804A4 (en) 2017-08-07 2021-04-14 Kura Oncology, Inc. METHOD OF TREATMENT OF CANCER WITH FERN SYL TRANSFERASE INHIBITORS
WO2019035951A1 (en) 2017-08-15 2019-02-21 Praxis Precision Medicines, Inc. COMPOUNDS AND THEIR METHODS OF USE
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
EP3672970A1 (en) 2017-08-22 2020-07-01 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
EP3684333A2 (en) 2017-09-21 2020-07-29 Neurocrine Biosciences, Inc. High dosage valbenazine formulation and compositions, methods, and kits related thereto
AU2018346500A1 (en) 2017-10-04 2020-04-02 The Regents Of The University Of California Immunomodulatory oligosaccharides
US10993941B2 (en) 2017-10-10 2021-05-04 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
WO2019074492A1 (en) 2017-10-10 2019-04-18 Obrien Christopher F METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
JOP20180092A1 (ar) 2017-10-13 2019-04-13 Gilead Sciences Inc مثبطات hiv بروتياز
US20200340060A1 (en) 2017-11-13 2020-10-29 Gilead Sciences, Inc. Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
EP3713916A1 (en) 2017-11-20 2020-09-30 Kiakos, Konstantinos 3,5-diarylidenyl-n-substituted-piperid-4-one-derived inhibitors of stat3 pathway acitivty and uses therof
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019118984A2 (en) 2017-12-15 2019-06-20 Solarea Bio, Inc. Microbial compositions and methods for treating type 2 diabetes, obesity, and metabolic syndrome
WO2019126136A2 (en) 2017-12-18 2019-06-27 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
CN111770755A (zh) 2017-12-28 2020-10-13 雷维瓦药品公司 治疗肺纤维化的方法
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
WO2019139871A1 (en) 2018-01-10 2019-07-18 Cura Therapeutics Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
TW202406538A (zh) 2018-01-10 2024-02-16 美商克拉治療有限責任公司 包含苯基磺醯胺之醫藥組合物及其治療應用
EP3743049A1 (en) 2018-01-24 2020-12-02 Purdue Pharma LP Sleep disorder treatment and prevention
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
KR20200141986A (ko) 2018-02-12 2020-12-21 다이어비티스-프리, 인크. 개선된 길항성 항-인간 cd40 단클론 항체
CA3089590C (en) 2018-02-15 2022-12-06 Gilead Sciences, Inc. Pyridine derivatives and their use for treating hiv infection
JP2021513972A (ja) 2018-02-16 2021-06-03 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 社会的機能障害の治療方法
CA3091259A1 (en) 2018-02-16 2019-08-22 Esperion Therapeutics, Inc. Sustained release formulations of bempedoic acid
CN116854630A (zh) 2018-02-16 2023-10-10 吉利德科学公司 用于制备可用于治疗逆转录病毒科病毒感染的治疗性化合物的方法和中间体
TW202000205A (zh) 2018-02-21 2020-01-01 美商Ａｉ治療公司 使用阿吡莫德與麩胺酸性劑的組合治療
JP7044416B2 (ja) 2018-02-28 2022-03-30 シャンハイ ダブリュディー ファーマシューティカル カンパニー，リミティド 薬物組成物およびその製造方法と使用
MX2020008972A (es) 2018-03-02 2020-10-05 Univ Oregon Health & Science Profármacos de amidas de moduladores de receptores nucleares de moléculas pequeñas.
CA3094391A1 (en) 2018-03-22 2019-09-26 The Children's Medical Center Corporation Methods and compositions relating to lung repair
US20190351031A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN112118886B (zh) 2018-05-23 2022-08-23 上海汉都医药科技有限公司 活性药物成分的控释系统及其制备方法
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
AU2019278814A1 (en) 2018-05-30 2020-12-17 Praxis Precision Medicines, Inc. Ion channel modulators
SG11202011862PA (en) 2018-06-13 2020-12-30 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
MX2020013004A (es) 2018-06-14 2021-02-17 Neurocrine Biosciences Inc Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
EP3814327A1 (en) 2018-06-29 2021-05-05 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
US11098027B2 (en) 2018-07-06 2021-08-24 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
EP3817818A1 (en) 2018-07-06 2021-05-12 Gilead Sciences, Inc. Therapeutic heterocyclic compounds
BR112021000315A2 (pt) 2018-07-11 2021-08-03 Actym Therapeutics, Inc. cepas bacterianas imunoestimulantes modificadas geneticamente e seus usos
CA3216031A1 (en) 2018-07-16 2020-01-23 Gilead Sciences, Inc. Capsid inhibitors for the treatment of hiv
MA53329A (fr) 2018-07-27 2022-03-02 Xenon Pharmaceuticals Inc Méthodes de traitement de l'épilepsie
TWI766172B (zh) 2018-07-30 2022-06-01 美商基利科學股份有限公司 抗hiv化合物
EP3814344B1 (en) 2018-08-07 2024-07-24 Firmenich Incorporated 5-substituted 4-amino-1h-benzo[c][1,2,6]thiadiazine 2,2-dioxides and formulations and uses thereof
JP2021528481A (ja) 2018-08-15 2021-10-21 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 特定のｖｍａｔ２阻害剤を投与するための方法
CN112912141A (zh) 2018-08-27 2021-06-04 斯皮诺吉尼克斯公司 用于树突棘生成的肌成束蛋白结合化合物
EP3843726B1 (en) 2018-08-27 2024-02-28 Oregon Health & Science University Parp inhibitors for treating cancer and asthma
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN112771067A (zh) 2018-08-29 2021-05-07 沙塔克实验室有限公司 包含基于SIRPα的嵌合蛋白的组合疗法
WO2020047312A1 (en) 2018-08-31 2020-03-05 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
KR20210054510A (ko) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도
WO2020051379A1 (en) 2018-09-05 2020-03-12 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases
US11980647B2 (en) 2018-09-05 2024-05-14 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
WO2020072835A1 (en) 2018-10-03 2020-04-09 Siteone Therapeutics, Inc. 11,13-modified saxitoxins for the treatment of pain
EP3860717A1 (en) 2018-10-03 2021-08-11 Gilead Sciences, Inc. Imidozopyrimidine derivatives
HRP20240541T1 (hr) 2018-10-31 2024-07-05 Gilead Sciences, Inc. Supstituirani spojevi 6-azabenzimidazola kao inhibitori hpk1
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
AU2019372141A1 (en) 2018-11-01 2021-05-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10570127B1 (en) 2018-11-05 2020-02-25 Renexxion, Llc Material and methods for the treatment of gastro-intestinal disorders
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
MD3880654T2 (ro) 2018-11-19 2022-05-31 Global Blood Therapeutics Inc Compuși 2-formil-3-hidroxifeniloximetilici capabili de modularea hemoglobinei
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
US20220144819A1 (en) 2018-11-20 2022-05-12 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
MA55143A (fr) 2018-11-20 2021-09-29 H Lee Moffitt Cancer Center & Res Institute Inc Composés aryl-aniline et hétéroaryl-aniline pour le traitement de cancers de la peau
EP3883554A4 (en) 2018-11-20 2022-11-23 NFlection Therapeutics, Inc. ARYL ANILINE AND HETEROARYL ANILINE COMPOUNDS FOR THE TREATMENT OF NEGAL MARKS
CA3120371A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
JP2022513159A (ja) 2018-11-29 2022-02-07 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Ｒｎａを調節する方法
CA3122996A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020123850A1 (en) 2018-12-13 2020-06-18 Global Blood Therapeutics, Inc. Ferroportin inhibitors and methods of use
US20230078755A1 (en) 2018-12-19 2023-03-16 Shy Therapeutics, Llc Compounds that Interact with the RAS Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease
KR20210106513A (ko) 2018-12-21 2021-08-30 쿠라 온콜로지, 인크. 편평 세포 암종을 위한 요법
WO2020132700A1 (en) 2018-12-21 2020-06-25 Fgh Biotech Inc. Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof
JP2022523146A (ja) 2019-02-06 2022-04-21 オレゴン ヘルス アンド サイエンス ユニバーシティ ビスホスホネート連結化合物
EP3921038A1 (en) 2019-02-06 2021-12-15 Dice Alpha, Inc. Il-17a modulators and uses thereof
CN113677681A (zh) 2019-02-11 2021-11-19 凤凰分子设计公司 Rsk抑制剂的结晶形式
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors
US11389438B2 (en) 2019-02-25 2022-07-19 Chdi Foundation, Inc. Compounds for targeting mutant huntingtin protein and uses thereof
WO2020176510A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176505A1 (en) 2019-02-25 2020-09-03 Gilead Sciences, Inc. Protein kinase c agonists
WO2020176809A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
EP3931180A1 (en) 2019-03-01 2022-01-05 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3132613A1 (en) 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Caspase inhibitors and methods of use thereof
JP2022525169A (ja) 2019-03-14 2022-05-11 サノビオン ファーマシューティカルズ インク イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
EP3712127A1 (en) 2019-03-22 2020-09-23 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
US11000488B2 (en) 2019-03-22 2021-05-11 Syntrix Biosystems Inc. Treating pain using desmetramadol
EP3941900A1 (en) 2019-03-22 2022-01-26 Deutsches Krebsforschungszentrum Novel inhibitors of histone deacetylase 10
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
TW202102218A (zh) 2019-04-01 2021-01-16 美商庫拉腫瘤技術股份有限公司 以法呢基(farnesyl)轉移酶抑制劑治療癌症的方法
JP2022527825A (ja) 2019-04-03 2022-06-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物送達のためのイオン液体
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202104210A (zh) 2019-04-17 2021-02-01 美商基利科學股份有限公司 Hiv蛋白酶抑制劑
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
WO2020223583A1 (en) 2019-05-02 2020-11-05 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
PE20220016A1 (es) 2019-05-03 2022-01-11 Praxis Prec Medicines Inc Inhibidores y metodos de uso de kcnt1
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
WO2020246503A1 (ja) 2019-06-03 2020-12-10 株式会社大分大学先端医学研究所 狂犬病治療のための環状アミド化合物およびその方法
TW202235416A (zh) 2019-06-14 2022-09-16 美商基利科學股份有限公司 Cot 調節劑及其使用方法
CA3143713A1 (en) 2019-06-19 2020-12-24 Solarea Bio, Inc. Microbial compositions and methods for producing upgraded probiotic assemblages
JP2022540083A (ja) 2019-07-08 2022-09-14 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルムを破壊するための抗体組成物
AU2020311404A1 (en) 2019-07-11 2022-03-03 Cura Therapeutics, Llc Sulfone compounds and pharmaceutical compositions thereof, and their therapeutic applications for the treatment of neurodegenerative diseases
EP3996746A4 (en) 2019-07-11 2023-08-23 Praxis Precision Medicines, Inc. FORMULATIONS OF T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF
AU2020310190A1 (en) 2019-07-11 2022-02-24 Cura Therapeutics, Llc Phenyl compounds and pharmaceutical compositions thereof, and their therapeutic applications
TW202118750A (zh) 2019-07-26 2021-05-16 美商艾斯佩維他治療學公司 官能化的長鏈烴一元及二元羧酸及其用於預防或治療疾病的用途
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
JP2022545917A (ja) 2019-08-27 2022-11-01 トニックス ファーマ リミテッド 修飾ｔｆｆ２ポリペプチド
MX2022003166A (es) 2019-09-16 2022-06-29 Dice Alpha Inc Moduladores de il-17a y usos de los mismos.
TW202126651A (zh) 2019-09-26 2021-07-16 美商艾克塞里克斯公司 吡啶酮化合物及使用方法
EP4034236A1 (en) 2019-09-26 2022-08-03 Abionyx Pharma SA Compounds useful for treating liver diseases
AU2020359526A1 (en) 2019-10-01 2022-04-21 Molecular Skin Therapeutics, Inc. Benzoxazinone compounds as KLK5/7 dual inhibitors
TW202128627A (zh) 2019-10-10 2021-08-01 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
AU2020376792A1 (en) 2019-11-01 2022-05-26 Lilac Therapeutics, Inc. Heterocyclic carboxylate compounds as glycolate oxidase inhibitors
CA3177479A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
EP4058456A1 (en) 2019-11-13 2022-09-21 RAPT Therapeutics, Inc. Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof
JP2023503899A (ja) 2019-11-22 2023-02-01 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 薬物送達のためのイオン液体
CA3157275A1 (en) 2019-11-26 2021-06-03 Elena BEKERMAN Capsid inhibitors for the prevention of hiv
PE20221280A1 (es) 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
AU2020396866A1 (en) 2019-12-02 2022-06-23 Celgene Corporation Therapy for the treatment of cancer
IL295677A (en) 2020-02-24 2022-10-01 Gilead Sciences Inc Tetracyclic compounds for the treatment of hiv inflammation
EP4110779A1 (en) 2020-02-24 2023-01-04 Exelixis, Inc. Compounds and methods of use
US20230093147A1 (en) 2020-03-09 2023-03-23 President And Fellows Of Harvard College Methods and compositions relating to improved combination therapies
CA3175541A1 (en) 2020-03-30 2021-10-07 Gilead Sciences, Inc. Solid forms of (s)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1h-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound
CA3176429A1 (en) 2020-03-31 2021-10-07 Global Blood Therapeutics, Inc. Modulators of hemoglobin
US20230159538A1 (en) 2020-04-01 2023-05-25 Global Blood Therapeutics, Inc. Pyrrolidine-pyrazoles as pyruvate kinase activators
CA3176061A1 (en) 2020-04-02 2021-10-07 Gilead Sciences, Inc. Process for preparing a cot inhibitor compound
EP4143178A1 (en) 2020-04-28 2023-03-08 Global Blood Therapeutics, Inc. Cycloalkyl pyrimidines as ferroportin inhibitors
US20230102247A1 (en) 2020-04-28 2023-03-30 President And Fellows Of Harvard College Methods and compositions relating to ionic liquid adjuvants
WO2021222359A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Thieno pyrimidines as ferroportin inhibitors
CA3181583A1 (en) 2020-04-28 2021-11-04 Global Blood Therapeutics, Inc. Methods of use for pyrimidines as ferroportin inhibitors
WO2021226033A1 (en) 2020-05-07 2021-11-11 President And Fellows Of Harvard College Hyaluronic acid drug conjugates
US11529331B2 (en) 2020-05-29 2022-12-20 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3′-diindolylmethane
EP4157923A2 (en) 2020-05-29 2023-04-05 President And Fellows Of Harvard College Living cells engineered with polyphenol-functionalized biologically active nanocomplexes
CA3186425A1 (en) 2020-06-10 2021-12-16 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
US20230227466A1 (en) 2020-06-18 2023-07-20 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
US20230102840A1 (en) 2020-06-23 2023-03-30 President And Fellows Of Harvard College Compositions and methods relating to combinatorial hyaluronic acid conjugates
CA3181690A1 (en) 2020-06-25 2021-12-30 Chienhung CHOU Capsid inhibitors for the treatment of hiv
JP2023532312A (ja) 2020-06-30 2023-07-27 プロセッタ バイオサイエンシズ， インク． イソキノリン誘導体、合成の方法及びそれらの使用
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US20230241171A1 (en) 2020-07-10 2023-08-03 Institut Pasteur Use of gdf11 to diagnose and treat anxiety and depression
WO2022031735A1 (en) 2020-08-03 2022-02-10 Global Blood Therapeutics, Inc. Urea derivatives as pyruvate kinase activators
CA3191433A1 (en) 2020-08-12 2022-02-17 Actym Therapeutics, Inc. Immunostimulatory bacteria-based vaccines, therapeutics, and rna delivery platforms
MX2023001741A (es) 2020-08-14 2023-04-25 Siteone Therapeutics Inc Inhibidores de cetonas no hidratadas de nav1.7 para el tratamiento de dolor.
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN116390924A (zh) 2020-09-30 2023-07-04 吉利德科学公司 桥连三环氨基甲酰基吡啶酮化合物及其用途
WO2022069701A1 (en) 2020-10-01 2022-04-07 Nogra Pharma Limited Methods of treating pulmonary fibrosis
WO2022090482A1 (en) 2020-10-30 2022-05-05 Ds Biopharma Limited Pharmaceutical compositions comprising 15-hetre and methods of use thereof
US11773088B2 (en) 2020-11-02 2023-10-03 Praxis Precision Medicines, Inc. KCNT1 inhibitors and methods of use
US20240059673A1 (en) 2020-12-22 2024-02-22 Gilead Sciences, Inc. Substituted indole compounds
EP4267560A1 (en) 2020-12-22 2023-11-01 Gilead Sciences, Inc. 6-substituted indole compounds
US20240117033A1 (en) 2021-01-15 2024-04-11 President And Fellows Of Harvard College Methods and compositions relating to anti-mfsd2a antibodies
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
EP4284394A1 (en) 2021-01-26 2023-12-06 Cytocares (Shanghai) Inc. Chimeric antigen receptor (car) constructs and nk cells expressing car constructs
EP4284377A1 (en) 2021-01-27 2023-12-06 Shy Therapeutics LLC Methods for the treatment of fibrotic disease
WO2022165000A1 (en) 2021-01-27 2022-08-04 Shy Therapeutics, Llc Methods for the treatment of fibrotic disease
TW202245758A (zh) 2021-02-08 2022-12-01 美商全球血液治療公司 作為丙酮酸激酶活化劑之吡咯啶-吡唑
TW202246283A (zh) 2021-02-09 2022-12-01 美商基利科學股份有限公司 噻吩并吡咯化合物
WO2022178205A1 (en) 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
WO2022187573A1 (en) 2021-03-05 2022-09-09 President And Fellows Of Harvard College Methods and compositions relating to cell membrane hybridization and camouflaging
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
CA3211505A1 (en) 2021-03-10 2022-09-15 Lalit Kumar Sharma Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
IL305676A (en) 2021-03-19 2023-11-01 Tiba Biotech Llc Expression systems of artificial RNA replicon derived from alphavirus
WO2022221642A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Thienopyrrole compounds
EP4326721A1 (en) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
JP2024520897A (ja) 2021-05-14 2024-05-27 グローバル ブラッド セラピューティクス インコーポレイテッド ヘモグロビン調節因子の固体形態
EP4347568A1 (en) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
TW202304435A (zh) 2021-06-04 2023-02-01 美商基利科學股份有限公司 治療ｎａｓｈ之方法
WO2022265880A1 (en) 2021-06-16 2022-12-22 President And Fellows Of Harvard College Improved methods and compositions for drug delivery relating to ionic liquids
WO2022266370A1 (en) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan for treating idiopathic pulmonary fibrosis
TW202311256A (zh) 2021-06-18 2023-03-16 美商基利科學股份有限公司 用於治療ｆｘｒ誘發之搔癢之ｉｌ－３１調節劑
WO2022271537A1 (en) 2021-06-25 2022-12-29 President And Fellows Of Harvard College Compositions and methods relating to injectable microemulsions
WO2023278843A2 (en) 2021-07-02 2023-01-05 Acer Therapeutics, Inc. Solid forms of osanetant
KR20240044458A (ko) 2021-08-05 2024-04-04 브리스톨-마이어스 스큅 컴퍼니 Her2 억제제로서 사용하기 위한 트리시클릭 융합된 피리미딘 화합물
WO2023034504A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin, modulating erythroid cell lineages, and perturbing megakaryocyte lineages
US20230144855A1 (en) 2021-09-01 2023-05-11 Flagship Pioneering Innovations Vi, Llc Methods and compositions for inducing fetal hemoglobin
WO2023034508A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for promoting adipocyte beiging
WO2023034507A1 (en) 2021-09-01 2023-03-09 Flagship Pioneering Innovations Vi, Llc In vivo and ex vivo methods of modulating t cell exhaustion/de-exhaustion
WO2023034530A1 (en) 2021-09-02 2023-03-09 Teon Therapeutics, Inc. Methods of improving growth and function of immune cells
WO2023039162A1 (en) 2021-09-09 2023-03-16 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating enteroendocrine cells
EP4399276A2 (en) 2021-09-09 2024-07-17 Flagship Pioneering Innovations VI, LLC Methods and compositions for modulating goblet cells and for muco-obstructive diseases
AU2022341114A1 (en) 2021-09-10 2024-02-29 Gilead Sciences, Inc. Thienopyrrole compounds
EP4402281A2 (en) 2021-09-14 2024-07-24 Flagship Pioneering Innovations VI, LLC Methods and compositions for perturbing monocyte and neutrophil lineages
KR20240070604A (ko) 2021-09-24 2024-05-21 제논 파마슈티칼스 인크. 소듐 채널 활성화제로서 피리디닐아세트아미드 유도체
CN118284602A (zh) 2021-09-24 2024-07-02 泽农医药公司 作为钠通道活化剂的吡啶衍生物及其用途
CN118251389A (zh) 2021-09-24 2024-06-25 泽农医药公司 作为钠通道活化剂的吡啶基衍生物
WO2023055457A1 (en) 2021-09-29 2023-04-06 Amneal Pharmaceuticals Llc Baclofen-containing granule formulations and reduced patient exposure to metabolite variations
WO2023060134A1 (en) 2021-10-06 2023-04-13 Global Blood Therapeutics, Inc. Lactam pyrrolidine-pyrazoles as pyruvate kinase activators
EP4162933A1 (en) 2021-10-08 2023-04-12 Algiax Pharmaceuticals GmbH Compound for treating non-alcoholic fatty liver disease and related diseases
WO2023059846A1 (en) 2021-10-08 2023-04-13 President And Fellows Of Harvard College Ionic liquids for drug delivery
AU2022368836A1 (en) 2021-10-22 2024-05-02 Prosetta Biosciences, Inc. Novel host-targeted pan-respiratory antiviral small molecule therapeutics
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
WO2023081730A1 (en) 2021-11-03 2023-05-11 Teon Therapeutics, Inc. 4-hydroxy-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carboxamide derivatives as cannabinoid cb2 receptor modulators for the treatment of cancer
AU2022391767A1 (en) 2021-11-22 2024-07-04 Solarea Bio, Inc. Methods and compositions for treating musculoskeletal diseases, treating inflammation, and managing symptoms of menopause
WO2023097230A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic bicyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
WO2023097234A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
WO2023097233A1 (en) 2021-11-23 2023-06-01 Genentech, Inc. Spirocyclic cyclic modulators of cholesterol biosynthesis and their use for promoting remyelination
AU2022399572A1 (en) 2021-11-30 2024-05-02 Kura Oncology, Inc. Macrocyclic compounds having farnesyltransferase inhibitory activity
AU2022401696A1 (en) 2021-12-03 2024-05-09 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CN118369316A (zh) 2021-12-03 2024-07-19 吉利德科学公司 Hiv病毒感染的治疗性化合物
AU2022399845A1 (en) 2021-12-03 2024-05-23 Gilead Sciences, Inc. Therapeutic compounds for hiv virus infection
CA3241881A1 (en) 2021-12-10 2023-06-15 Global Blood Therapeutics, Inc. Methods of administering a modulator of hemoglobin
US20230190834A1 (en) 2021-12-21 2023-06-22 Solarea Bio, Inc. Immunomodulatory compositions comprising microbial entities
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
US11981694B2 (en) 2022-01-03 2024-05-14 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023137178A1 (en) 2022-01-17 2023-07-20 Chandrasekhar Satishchandran Combinations of vitamin d3, niacinamide and lipoic acid for use in the maintenance of healthy blood glucose levels
WO2023147135A1 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Nk receptor antagonists for treatment of prostate cancer
WO2023147134A2 (en) 2022-01-31 2023-08-03 Acer Therapeutics, Inc. Methods for treating patients having low estrogen with nk3 antagonists
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
WO2023178283A1 (en) 2022-03-18 2023-09-21 Epicentrx, Inc. Co-crystals of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone and methods
US20230303580A1 (en) 2022-03-28 2023-09-28 Isosterix, Inc. Inhibitors of the myst family of lysine acetyl transferases
US20230348909A1 (en) 2022-03-30 2023-11-02 Biomarin Pharmaceutical Inc. Dystrophin exon skipping oligonucleotides
WO2023192506A1 (en) 2022-03-31 2023-10-05 Rarified Biosciences, Inc. Malt1 modulators and uses thereof
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
TW202400172A (zh) 2022-04-06 2024-01-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TW202406901A (zh) 2022-04-14 2024-02-16 美商必治妥美雅史谷比公司 新穎gspt1化合物以及新穎化合物之使用方法
WO2023201348A1 (en) 2022-04-15 2023-10-19 Celgene Corporation Methods for predicting responsiveness of lymphoma to drug and methods for treating lymphoma
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2023215227A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Systems and methods to improve exercise tolerance
WO2023215229A1 (en) 2022-05-02 2023-11-09 Epicentrx, Inc. Compositions and methods for treatment of pulmonary hypertension
WO2023215220A1 (en) 2022-05-02 2023-11-09 Esperion Therapeutics, Inc. Macrocyclic inhibitors of atp citrate lyase
WO2023215781A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. Method of treating duchenne muscular dystrophy
WO2023225162A1 (en) 2022-05-20 2023-11-23 Gilead Sciences, Inc. Antiviral indolinyl compounds and uses thereof
WO2023230524A1 (en) 2022-05-25 2023-11-30 Flagship Pioneering Innovations Vi, Llc Compositions of secretory and/or catalytic cells and methods using the same
TW202404583A (zh) 2022-06-08 2024-02-01 加拿大商再諾製藥公司 吡啶胺衍生物及其作為鉀通道調節劑之用途
WO2023240186A1 (en) 2022-06-08 2023-12-14 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
TW202408485A (zh) 2022-06-13 2024-03-01 美商埃皮辛特瑞科斯公司 用於減少癌症治療中不良副作用之組合物及方法
US12018009B2 (en) 2022-06-14 2024-06-25 Amygdala Neurosciences, Inc. ALDH-2 inhibitor compounds and methods of use
US20230399299A1 (en) 2022-06-14 2023-12-14 Amygdala Neurosciences, Inc. Aldh-2 inhibitor compounds and methods of use
WO2024015827A1 (en) 2022-07-12 2024-01-18 Hotspot Therapeutics, Inc. Solid forms of a triazine derivative as cbl-b modulator
WO2024015372A1 (en) 2022-07-14 2024-01-18 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
WO2024015416A1 (en) 2022-07-15 2024-01-18 Celloram Inc. Celastrol derivatives
TW202410893A (zh) 2022-08-31 2024-03-16 日商大塚製藥股份有限公司 用於治療t細胞淋巴瘤之結合治療
US20240158370A1 (en) 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS
US20240131005A1 (en) 2022-09-30 2024-04-25 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
WO2024086246A2 (en) 2022-10-18 2024-04-25 Eluciderm Inc. 2-substituted 3,4 a, 5, 7, 8, 8 a-hexahydro-4h-thiop yrano [4,3- djpyrimidin-4-ones for wound treatment
WO2024091863A1 (en) 2022-10-25 2024-05-02 Starrock Pharma Llc Combinatorial, and rotational combinatorial therapies for obesity and other diseases
WO2024092037A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing pyridone compounds
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
WO2024092040A1 (en) 2022-10-26 2024-05-02 Protego Biopharma, Inc. Spirocycle containing bicyclic heteroaryl compounds
WO2024089668A1 (en) 2022-10-28 2024-05-02 Basecamp Bio Inc. Somatostatin receptor 2 agonists and uses thereof
WO2024097940A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Therapy for the treatment of cancer
WO2024098009A1 (en) 2022-11-04 2024-05-10 Epicentrx, Inc. Rrx-001 for minimizing post-infarct adverse ventricular remodeling and complications
WO2024118801A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Linear heteroaryl diamide ire1/xbp1s activators
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
WO2024124152A1 (en) 2022-12-08 2024-06-13 Epicentrx, Inc. Rrx-001 for the treatment of a hemoglobinopathy
US11931224B1 (en) * 2022-12-19 2024-03-19 Robert Parker Tooth pod
WO2024145662A1 (en) 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1023499A (en) * 1910-09-20 1912-04-16 Ralcy Husted Bell Collapsible capsule.
US1279564A (en) * 1918-02-28 1918-09-24 Frederick Stearns & Company Method of forming medicine-injectors.
US1434531A (en) * 1919-01-29 1922-11-07 Lloyd W Cyrenius Ampullar container for liquids or semisolids
US2846057A (en) * 1954-02-09 1958-08-05 Polin Herbert Spencer Devices for dosage control
US2962023A (en) * 1955-10-28 1960-11-29 Chappaz Gaston Medicator
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3574820A (en) * 1968-01-08 1971-04-13 Upjohn Co Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert

Also Published As

Publication number Publication date
US3845770A (en) 1974-11-05
NL163721B (nl) 1980-05-16
ES415568A1 (es) 1976-05-16
BR7304196D0 (pt) 1974-07-25
JPS4961325A (nl) 1974-06-14
IE39952L (en) 1973-12-05
IE39952B1 (en) 1979-02-14
AR199301A1 (es) 1974-08-23
CH578464A5 (nl) 1976-08-13
GB1415210A (en) 1975-11-26
NL163721C (nl) 1980-10-15
JPS596843B2 (ja) 1984-02-15
IL42418A0 (en) 1973-07-30
ZA733734B (en) 1974-06-26
FR2188568A5 (nl) 1974-01-18
NL7307699A (nl) 1973-12-07

Similar Documents

Publication Publication Date Title
IL42418A (en) An osmotic device for dispensing an active agent at a controlled rate
ZA739622B (en) Dispensing device
JPS56127548A (en) Device for discharging article little by little
ZA734105B (en) Device for dispensing medicaments
CA989781A (en) Aerosol dispensing device
IL41876A0 (en) Fluid dispensing nozzle
CA996073A (en) Dispensing device
IL41185A (en) Electromagnetically controlled dispensing apparatus
IE37810L (en) Device for use with a pressurised dispensing container
ZA726621B (en) Distributing device for a sowing machine
CA976440A (en) Metering device for a liquid pump
IE38672L (en) Sustained release dispensing device
IL43208A0 (en) Seed dispensing device
YU78973A (en) Device for deposition welding
IE37349L (en) Dispensing apparatus
ZA739347B (en) Pressurised dispenser
IE38993L (en) Locating device for reinforcement members
GB1398579A (en) Liquid dispensers for animals
CA963577A (en) Liquid dispensing machine
AU487451B2 (en) Device for dispensing medicaments
CA897644A (en) Dispensing device
IL41519A0 (en) Device for dispensing ice
CA957267A (en) Unit dose packaging device
CA903151A (en) Pressurized dispensing device
AU474113B2 (en) Nozzle for liquid dispenser